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Psychoactive Substances and Paranormal Phenomena: 
A Comprehensive Review
This paper investigates the relationship between psychoactive substances and so-called paranormal 
phenomena falling within the study of parapsychology. It is primarily concerned with extrasensory 
perception (ESP)—telepathy, precognition, and clairvoyance—as well as out-of-body experiences 
(OBEs) and near-death experiences (NDEs). Psychokinesis (PK), aura vision, encounter experiences, 
and sleep paralysis only make a very limited contribution to this review as they are seldom related 
to psychoactive drugs within the parapsychological literature. The paper borrows widely, but by no 
means exhaustively, from parapsychology as well as transpersonal studies, anthropology, ethnobotany, 
phytochemistry, psychiatry, psychotherapy, psychopharmacology, and neurobiology, particularly 
neurochemistry. It is organized into neurochemical models of paranormal experience (section 1), 
field reports of intentional and spontaneous phenomena incorporating anthropological, historical 
and clinical cases, and personal accounts (section 2), surveys of paranormal belief and experience 
(section 3), experimental research (section 4), and a methodological critique of the experimental 
research with recommendations for further work (section 5). 
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Ever since the beginning of the 20th century when Western scientists and academics began earnestly turning their attention to psychedelics 
there has been a clear association between the use of 
these substances and the transpersonal or paranormal 
experience. Indeed, those people most readily associated 
with the discovery and popularization of psychedelics 
also witnessed and explored both the transpersonal and 
the parapsychological dimensions that these substances 
induced, such as Albert Hofmann, Humphrey Osmond, 
John Smythies, Aldous Huxley, Gordon Wasson, 
Timothy Leary, Ken Kesey, Duncan Blewett, Walter 
Pahnke, James Fadiman, and Stanislav Grof, to name but 
a few (Luke, 2006; Stevens, 1988). The overlap between 
transpersonal and paranormal experiences is apparent 
(e.g., Daniels, 2005), but while a great deal has been 
written in recent years about psychedelic experiences 
from the transpersonal perspective, a comprehensive 
review of the parapsychological literature relating to 
psychedelic experiences is long overdue. 
This review focuses primarily on the class of 
psychoactive substances that largely induce visionary and 
trance-like experiences. For the purposes of the present 
review this includes drugs and sacramentals such as 
mescaline, lysergic acid diethylamide (LSD), psilocybin, 
ayahuasca, N,N-dimethyltryptamine (DMT), marijuana 
(which is treated as a psychedelic in the current review), and 
ketamine, but not opiates or cocaine. This class of visionary 
substances has been termed differently by different authors, 
usually dependent upon the connotation they wish to 
convey about the psychoactive effects or how the substance 
is used. Within the literature of the present review, they 
have been termed “mind-expanding” (e.g., Palmer, 1979), 
“psychotropic” (e.g., Irwin, 1994), “psychodysleptic” 
(Cavanna & Servadio, 1964), “hallucinogenic” (e.g., 
Blackmore, 1992), and even “entheogenic” (Ruck, 
Bigwood, Staples, Wasson, & Ott , 1979), meaning 
bringing forth the divine within, which is a useful term 
to convey the apparent divinatory and visionary nature 
of these substances (for discussions see Letcher, 2004; 
Ott, 1996; Smith, 2000), although they might be more 
correctly termed “potential entheogens” as they do not 
automatically produce such experiences (Krippner, 2006b, 
p. 1). Finally, there is the most frequently used term, 
“psychedelic”, which was created in 1956 by Humphry 
Osmond and means “mind manifesting” (Osmond, 
1961a, p. 76). Where specified, the original term used by 
the authors will be preserved to reflect their orientation to 
the issue. However, elsewhere, where appropriate, the more 
widely used term “psychedelic” will be used.
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For the purpose of the present paper, a 
psychedelic drug is:
one which, without causing physical addiction, 
craving, major physiological disturbances, delirium, 
disorientation, or amnesia, more or less reliably 
produces thought, mood, and perceptual changes 
otherwise rarely experienced except in dreams, 
contemplative and religious exaltation, flashes of 
vivid involuntary memory, and acute psychoses. 
(Grinspoon & Bakalar, 1998, p. 9)
The earliest parapsychology experiments with psycho-
active substances were conducted with simple stimulants 
and depressants, such as caffeine, amphetamine, alcohol, 
amytal, and quinal-barbitone (e.g., Averill & Rhine, 
1945; Cadoret, 1953; Huby & Wilson, 1961; Murphy, 
1961; Rhine, 1934; Rhine, Humphrey, & Averill 1945; 
Soal & Bateman, 1954; Wilson, 1961, 1962; Woodruff, 
1943). This work is not included here (for reviews see 
Palmer, 1978; Ramakrishna Rao, 1966) as this review is 
instead focused on the visionary substances, which are 
seemingly more favorable to the production of psi, that 
Braud (2002) has suggested primarily cause qualitative, 
rather than just quantitative alterations to the user’s state 
of consciousness, although Rock and Krippner (e.g., 2012) 
argued that (altered) states of consciousness may be more 
accurately described as (altered) states of phenomenology. 
Some earlier reviews of psychedelics in parapsychology 
are available and have been incorporated into the present 
investigation (Blewett, 1963; Gowan, 1975; Krippner & 
Davidson, 1970, 1974; Luke, 2008b; Luke & Friedman, 
2010; Parker, 1975; Rogo, 1976; Wilson, 1949).
There are good theoretical reasons for 
investigating psychedelics as a means of inducing ESP 
and other paranormal phenomena. Given that an 
altered state of consciousness (ASC) is assumed to be 
(for a discussion see Storm & Rock, 2009) a common 
feature in the occurrence of subjective paranormal 
experiences (Alvarado, 1998; Barušs, 2003; Honorton, 
1977; Parker, 1975) and has often been incorporated into 
experimental attempts to induce ESP (see Luke, 2011a; 
Palmer, 1978, 1982; Schmeidler, 1994), then visionary 
drugs are, potentially, a reliable means of accessing such 
a state. Several researchers have documented some of the 
mind-altering features of the visionary-drug experience 
that are considered conducive to the production of 
parapsychological experiences and phenomena (see also 
Braud, 2002). These have been categorized thus:
1.    Increase in mental imagery, in both vividness and 
quality, and the dreamlike state (Blackmore, 
1992; Osis, 1961a, 1961b; Progoff, 1961; Tart, 
1968, 1994) 
2.  Altered perception of self-identity, such as unity 
consciousness: The mystical experience of 
becoming one with everything in the universe 
(Krippner & Fersh, 1970; Nicol & Nicol, 1961; 
Osis, 1961a; Pahnke, 1968; Tart, 1994)
3.  Altered body perceptions and dissociation 
(Blackmore, 1992; Tart, 1994). This is of 
particular interest with respect to the out-of-
body experience (OBE)
4.    Distorted sensory input (Blackmore, 1992)
5.   Increased absorption and focused attention 
(Millay, 2001; Tart, 1968, 1994)
6.   Increased empathy (Blewett, 1963; Nicol & 
Nicol, 1961; Tart, 1994). This is of interest to 
telepathy, and indeed, elevated empathy is 
associated with use of psychedelics generally 
(DeGracia, 1995; Lerner & Lyvers, 2006)
7.    Emotional flexibility (Blewett, 1963), which may 
also assist in negotiating the fear of psi (Tart, 1994)
8.   Increased alertness and awareness (Huxley, 
1961a; Nicol & Nicol, 1961; Osis, 1961b; Tart, 
1994)
9.  Increased inwardly focused attention and 
awareness, and decreased external and bodily 
awareness (Dobkin de Rios, 1978)
10.  Increased spontaneity (Osis, 1961a)
11. Sensitivity to subtle changes (Parker, 1975) and 
intensity of feeling (Osis, 1961a)
12.  Physical relaxation (Blackmore, 1992), although 
Tart (1968) questions its occurrence
13.  Increased suggestibility (Huxley, 1961a; Tart, 1968)
14.   Increase in intuitive thought processes (Tart, 1994)
15.   Reduced critical conscious faculty and increased 
optimism towards impossible realities (Nicol & 
Nicol, 1961; Osis, 1961b; Tart, 1968, 1994)
16.    Increased openness and extroversion (Rogo, 
1976)
17.    Release of repressed and unconscious material into 
the conscious mind (Rogo, 1976)
18.     Complex distortions, and transcendence, of space 
 and time (Garrett 1961b; Nicol & Nicol, 1961; 
Tart, 1994; see also Dawson, 2005; Mayhew, 
1956; Shanon, 2001; Whiteman, 1995)
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 This last feature of the psychedelic experience is 
probably of paramount importance for the experience of 
ESP when it is considered that precognition, telepathy, 
clairvoyance, and possibly OBEs all represent radical 
departures from Newtonian concepts of time and space. 
Smythies (1983) has suggested that the psychedelic 
experience originates from the collective unconscious 
outside of space and time, and Jung agreed with 
Smythies’ idea. Millay (2001) offered that psilocybin 
and similar substances are important for studying psi 
because they allow us access to nonlocal space-time. 
Jansen (1999) also supposed that the same might be 
possible of ketamine, which became popularly used at the 
same time as Bell’s theorem of nonlocal space-time was 
becoming seriously considered, enabling some to report 
the experiential equivalence of the concept. Indeed, the 
Berkley-based Fundamental Fysiks Group that formed 
in the 1970s experimented with psychedelics to inspire 
their investigations of both psi and Bell’s theorem—
neglected as it was by mainstream physics at that time 
—which eventually lead to the birth of what is now 
the multi-billion dollar research enterprise of quantum 
information science (Kaiser, 2011). More recently, 
something akin to this may also be evident with the 
psychedelic substance DMT, which sometimes provides 
users with the perception of many more than the usual 
four space-time dimensions, perhaps comparable to what 
physicists discuss in M-theory (Luke, 2010c). Keeping 
with the times ketamine is also now reported to induce 
such extra-dimensional percepts too (Newcombe, 
2008), as is the semi-synthetic psychedelic salvinorin B 
ethoxymethyl ether (Mercury & Feelodd, 2008). 
In addition to these temporary alterations that 
occur during the psychedelic experience, it is arguable 
that long-term ideological alterations may occur that 
might also be psi-conducive. For example, enduring 
changes in concepts of reality may occur with the use of 
psychedelics (Conway, 1989; Strassman, 2001), such that 
optimism about unseen realities, both during and after 
the experience, leads to a greater openness to, or belief 
in, psi and the paranormal. In a follow-up survey of 113 
LSD-psychotherapy clients (with an 82% response rate) 
78% reported an increased tendency to view telepathy 
and precognition as possibilities warranting investigation 
(International Foundation for Advanced Study, 1962). It 
has even been stated that the psychedelic experience is 
itself, by common consent, paranormal (Unger, 1963). 
Furthermore, the distinguished medium and psychical 
researcher Eileen Garrett (1961b) asserted that the use of 
LSD had made her a better, more accurate sensitive and 
she related certain psychedelic states to the mediumistic 
pre-trance state of euphoria, although she specified that 
the LSD experience was not the same as the mediumistic 
trance (Garrett, 1961a). Huxley (1961a) proposed that 
LSD is invaluable in training participants to use their 
subjective faculties to enhance their psi ability.
Besides the subjective aspects of the 
psychedelic experience, there are other theoretical 
reasons for investigating paranormal phenomena with 
drugs: Because paranormal phenomena are brain-
mind experiences, neurochemicals—and therefore 
psychoactive drugs—would be expected to be involved 
in the process. It is highly likely that all ASC, including 
potentially ESP-conducive states, involve alterations 
in brain chemistry. Indeed, several psychedelic-
neurochemical models, discussed in the following 
sections (also see Luke & Friedman, 2010), have been 
proposed, primarily based upon subjective paranormal 
experiences occurring with certain substances and their 
specific neurochemical action. It is entirely feasible that 
genuine paranormal experiences are mediated in the 
brain through the action of specific endogenous (made 
within the body) molecules (Vayne, 2001). This does not 
simply imply that neurochemicals are the sole cause of 
paranormal phenomena, but they may rather just be a 
part of the process. As the novelist Aldous Huxley once 
said in relation to mystical experiences and the use of 
psychedelics—they are the occasion rather than the 
cause. 
1. Psychedelic/Neurochemical Models 
of Paranormal Experience
1.1 Brain as filter 
 Aldous Huxley (1954) also was prominent in 
promoting Henri Bergson’s (1896/1990) theory of the 
brain as a filter of memory and sensory experience, 
acting to reduce the wealth of information available 
to awareness lest people become overwhelmed by a 
mass of largely useless and irrelevant data not needed 
for the survival of the organism. It was Bergson who 
suggested that, if these filters were bypassed, humans 
would be capable of remembering everything that 
had ever been experienced and perceiving everything 
that has happened everywhere in the universe (e.g., as 
in clairvoyance). It was also Huxley who applied this 
theory to psychedelics by suggesting that these mind-
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manifesting drugs override the “reducing valve” of the 
brain (Huxley, 1954, p. 12), allowing humans access to 
both psychic and mystical experiences. This was a notion 
that Huxley eruditely paraphrased for the title of his 
book from the quote by the English poet and mystic, 
William Blake (1906/1793), “If the doors of perception 
were cleansed, every thing would appear to man as it is, 
infinite” (p. 26). 
Huxley’s (1954) rather basic conception never 
received a more formal operationalization of the specific 
drug actions that may be involved, but research into the 
neurochemistry of psychedelics lends some support to 
his notion. For instance, Vollenweider and Geyer (2001) 
proposed that information processing in cortico-striato-
thalamo-cortical (CSTC) feedback loops is disrupted 
by psychedelics via 5-HT (serotonin) receptor agonism 
(specifically 5-HT2A receptors), thereby inhibiting the 
“gating” of extraneous sensory stimuli and inhibiting 
the ability to attend selectively to salient environmental 
features. Furthermore, psychedelics are also thought to 
induce presynaptic release of glutamate from thalamic 
afferents, leading to a simultaneous overload of internal 
information in the cortex. It is thought that these 
combined information overload effects are at least partly 
responsible for the hallucinogenic experience with these 
drugs, which are known to induce greatly altered or 
amplified incoming sensory information, as is indicated 
by an increased startle effect (Vollenweider, 2001). 
Research into the neurobiology of psychedelics 
in humans has only just resumed after decades of 
dormancy, so the current understanding of the action 
of these substances in the brain remains limited. One of 
the few studies to have been conducted, however, also 
offers some unexpected support for Huxley’s reducing 
valve theory. Looking at the blood flow around the brain 
following the ingestion of psilocybin, it was expected 
that certain regions of the brain would have more 
activity, given the overwhelming intenseness of strong 
psychedelic experiences, and yet, counter-intuitively, 
there was no single brain region that increased in 
activity, and the brain’s activity was reduced overall 
(Carhart-Harris, 2011; Carhart-Harris et al., 2012). 
The main areas demonstrating reduced cerebral blood 
flow were the cerebral hub regions of the thalamus, 
anterior and posterior cingulate cortex (ACC & PCC), 
and medial prefrontal cortex (mPFC). Significantly, 
the usual positive coupling between the mPFC and the 
PCC—which forms part of the default mode network 
thought to be important in introspection and high level 
constructs such as self and ego—was reduced leading to 
“a state of unconstrained cognition” (Carhart-Harris et 
al., 2012, p. 2138).
This psychedelic disruption of the sensory 
gating function discussed by Vollenweider (2001), 
and the reduction of activity in the default mode 
network discussed by Carhart-Harris (2011) could also 
underpin the neurochemistry of ESP, whether elicited 
with any number of psychedelics or, indeed, without 
the intervention of such exogenous chemicals (though 
perhaps via endogenous chemicals such as DMT). 
Indeed like psychedelics, psi experiences and events 
have variously been conceptualized in relation to an 
inhibition of the ordinary sensory inhibition, often 
in conjunction with elevated psychosis and creativity, 
such as with the concepts of latent disinhibition (Holt, 
Simmonds-Moore, & Moore 2008), transliminality 
(Thalbourne, 2000; Thalbourne & Houran, 2005), 
boundary thinness and schizotypy (Simmonds & Roe, 
2000), and self-expansiveness (Friedman, 1983; Pappas 
& Friedman, 2007). It may be noted that psychedelics 
have also been long associated with both creativity (e.g., 
Dobkin de Rios & Janiger, 2003; Krippner, 1985) and 
psychosis (Osmond & Smythies, 1952). 
Despite the simplistic appeal of the anti-
reducing valve action of psychedelics as a neurochemical 
model of psi, considerable gaps still remain in the 
current understanding of the neuropharmacological 
action of psychedelics in humans. Since the early 1970s, 
until relatively recently, practically all psychedelic 
research has been conducted with animals and there 
remain no definitive generalizations that can be made 
about the main neurotransmitter receptor sites involved, 
as psychedelics vary considerably in their chemical 
makeup and their ligand (i.e., a ligand is a molecule, 
such as a neurotransmitter, that triggers a response 
in a target protein) affinity (Ray, 2010). For instance, 
dissociative anesthetics such as ketamine are commonly 
N-methyl-D-aspartate (NMDA) receptor antagonists, 
whereas the simple tryptamines, such as psilocybin, 
are apparently 5-HT2A agonists. Speculations about 
the cause of the hallucinogenic effects of psychedelics 
generally include the activation of 5-HT1A, 5-HT2A, 
5-HT2C, dopamine, and glutamate pathways, although 
it is generally believed that classic psychedelics primarily 
work by stimulating 5-HT2A receptors, particularly 
those expressed in the neocortical pyramidal cells (Lee 
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& Roth, 2012; Nichols, 2004), although this is certainly 
not the case for all psychedelics (e.g., mescaline; Ray, 
2010). Electrophysiology and receptor studies have 
revealed that both NMDA antagonists (e.g., ketamine) 
and classic serotonergic psychedelics (e.g., LSD) may 
actually enhance glutamatergic transmission via non-
NMDA receptors in the frontal cortex. This may 
indicate a common mode of chemical action in the 
brain responsible for such similar experiences with these 
divergent molecules (Vollenweider, 2004); this serotonin/
glutamate receptor-complex model of drug action is 
receiving high-profile attention again for psychedelics 
as a possible comparative model of psychosis (e.g., 
González-Maeso et al., 2008). 
Despite the lack of understanding of the 
neurobiology of psychedelic action, and lack of 
generalizability across so many diverse substances, recent 
advances would appear to support the Bergson-Huxley 
notion of brain as a filter capable of being deactivated 
by chemicals, and furthermore this notion, including the 
parts pertaining to ESP, is now gaining ground once more 
among theorists of consciousness (e.g., Kastrup, 2012). 
Indeed, recent theoretical developments (Smythies, 2011) 
suggest that NMDA antagonism, such as via ketamine, 
bypasses the reducing valve/filter action of the brain (see 
section 1.4 following below for a discussion).
1.2 β-carbolines, tryptamines, and psi
Advancing on earlier suggestions about the 
pineal gland’s involvement in psi (e.g. Miller, 1978; 
Sinel, 1927), Roney-Dougal (1986, 1989, 1991, 2001) 
has developed an endogenous neurochemical-perspective 
of psi based on the action of the pineal and several 
hallucinogenic substances found in ayahuasca, the 
visionary Amazonian brew reported to induce a range of 
paranormal experiences. The common neurotransmitter 
serotonin is known to be most active in the pineal gland, 
where it follows a circadian rhythm and is converted at 
night into melatonin (5-methoxy tryptamine, or 5MT) 
and the β-carboline, pinoline (6-methoxy tetrahydro-
β-carboline, or 6-MeO-THβC), which regulate sleep 
cycles. The pineal may also create other β-carbolines, 
such as 6-methoxyharmalan, a harmala alkaloid. These 
β-carbolines block the neuronal uptake of serotonin 
making it available for use, and inhibit the enzyme 
monoamine oxydase (MAO), which breaks down certain 
tryptamines such as N,N-dimethyl tryptamine (N,N-
DMT, or simply DMT) and 5-methoxy tryptamine 
(5-MeO-DMT). MAO inhibiters, such as pinoline 
or the harmala alkaloids, make serotonin available 
at the pineal where, with the aid of pineal enzymes 
(methyl transferases), it can also be converted into 
5-MeO-DMT, DMT, and bufotenine (5-hydroxy-
N,N-dimethyltyptamine, 5-HO-DMT), which are 
endogenous visionary substances also found in certain 
ingredients (such as Psychotria viridis) of ayahuasca brews 
and other shamanic visionary substances, even some of 
animal origin (e.g., the Sonoran desert toad, Rudgley, 
2000). In vivo biosynthesis of DMT might also occur 
through the conversion of the common, nutritionally 
essential, amino acid tryptophan (Jacob & Presti, 2005; 
Shulgin & Shulgin, 1997). 
However, these endogenous visionary 
tryptamines are not orally active, as they are denatured by 
the MAO enzymes present in the stomach, but ayahuasca 
brews also contains plant additives (such as Banisteriopsis 
caapi) containing a range of harmala alkaloids that 
inhibit MAO and allow the complementarily ingested 
visionary tryptamines to be active in the brain. It is 
this action of the β-carbolines (particularly harmine) 
in ayahuasca that is these days considered their primary 
purpose as admixtures in the brew (e.g., McKenna, 
2004), though this may not always be the case as 
subjectively potent ayahuasca decoctions occasionally 
do not actually contain DMT when analyzed (Callaway, 
2005). Nevertheless the harmala alkaloids are also known 
to induce visions themselves and Roney-Dougal (1986, 
1989, 1991, 2001) originally implicated β-carbolines, 
such as the endogenous pinoline and the exogenous 
harmala alkaloids, as inducing psi-conducive states, either 
naturally during dreams (Callaway, 1988) or artificially 
by causing waking dream states. Roney-Dougal (2001) 
also later acknowledged that the β-carbolines may exert 
their visionary effects by potentiating the effects of 
ingested visionary tryptamines like DMT or 5-MeO-
DMT when consumed in combination with them, as 
in ayahuasca. Further to Roney-Dougal’s proposals, it 
is my speculation that the β-carbolines may also induce 
visions by contributing to the endogenous manufacture 
of visionary tryptamine substances, either when taken 
alone or in combination with such tryptamines, perhaps 
even indicating endogenous DMT or related tryptamines 
as the primary or even sole cause of such visions. This 
may account for why harmala alkaloids are less effective 
and slower than DMT at inducing visions (see Shulgin 
& Shulgin, 1997). In essence, ayahuasca contains two 
types of visionary chemicals, one type (β-carbolines, 
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e.g., harmine) that helps to both create and potentiate 
the effects of the other type (tryptamines, e.g., DMT), 
potentially mimicking the nocturnal chemistry of the 
pineal and its supposed control over natural visionary 
states, such as dreams (Callaway, 1988), mystical 
experiences, and NDEs (Strassman, 2001). 
Roney-Dougal (1989, 1991, 2001) suggested 
that the pineal gland and its neurochemistry is important 
in the occurrence of psi phenomena and points to the 
association made by yogis between the pineal gland and 
the ajna chakra, the yogic psychic center that controls 
psi-experiences in those with awakened kundalini 
(Miller, 1978; Satyananda, 1972). Further to this, 
Naranjo (1987) noted that both kundalini and ayahuasca 
experiences, being similar in many respects, also feature 
the same serpentine imagery, further speculating that 
they probably have the same neurochemistry and result 
in the same bioenergetic activation. 
There is also some possibility that pineal gland 
activity or DMT production can be stimulated by 
certain esoteric yogic practices, such as kechari, which 
involves pressing the tongue into the far rear roof of 
the mouth to stimulate the production of amrit, a yogic 
nectar that reputedly causes DMT-like ecstasies, which 
is supposedly secreted in the brain following prolonged 
practice (Motoyama, 2001; Satyananda, 1996). Some 
support for this speculation comes from Strassman’s 
(2001) observation that the pineal gland is formed in 
utero from the tissue of the roof of the mouth rather 
than in the brain, and later migrates to its unique 
ventricle position just outside the blood-brain barrier, 
directly above a critical cerebrospinal fluid byway, and 
this tentatively suggests that pineal stimulation via 
the roof of the mouth may be possible. Furthermore, 
manifestation of very specific body vibrations said to be 
classic kundalini symptoms are supposedly quite reliably 
induced with substances such as DPT (N,N-dipropyl-
tryptamine) and 4-Acetoxy-DIPT (N,N-diisopropyl-
4-acetoxy-tryptamine), which are even more obscure 
psychedelic tryptamines than DMT, but close relatives 
of it (Toad, 1999a, 1999b). Similarly, Grof (2001) has 
reported spontaneous kundalini arousal occurring 
during psychedelic psychotherapy sessions and surveys 
(see section 3.2.3 & 3.2.4 to follow) of kundalini 
experiences have found them to be related to drug use 
(DeGracia, 1995; Thalbourne, 2001). 
Roney-Dougal (1989, 1991, 2001) also indicated 
that the pineal gland is sensitive to—possibly changing 
its chemical production—the same fluctuations in 
geomagnetic activity that appear to be associated with 
spontaneous psi-activity, possibly related to pineal 
melatonin (Persinger, 1988) or DMT fluctuations 
(Hill & Persinger, 2003)—for a review see Roney-
Dougal, Ryan, and Luke (2012). That the pineal gland 
is central to psi is further supported by anthropological 
research, to follow—although experimental evidence 
is lacking—that suggests that DMT and the harmala 
alkaloids found in ayahuasca are psi-conducive, along 
with clinical research that suggests that pinoline and 
melatonin regulate sleep cycles and dreaming, during 
which spontaneous psi experiences most often occur 
(Roney-Dougal, 1986, 1989, 1991, 2001). Durwin 
(2001) has further suggested that the total isolation in 
the dark undergone for either the first 9 or 18 childhood 
years of the lives of trainee shamans of the Andean 
Kogi causes pineal gland deformation (presumably by 
melatonin/pinoline overproduction) that is responsible 
for their renowned divinatory skills. 
Some tentative support for the notion that 
ESP performance is directly predicted by pineal gland 
activity is also evident with experimental research that 
demonstrated prepubescent children score better on ESP 
tests at 3 a.m., when the pineal’s nocturnal chemicals 
(melatonin, etc.) are supposedly at peak concentrations 
in the brain, rather than at 9 p.m. (Satyanarayana, Rao, 
& Vijaylakshmi, 1993). This effect was not evident with 
a comparable group of pubescent children, which the 
authors suggest might be expected because the pineal 
is less active after infancy. A more extensive follow-up 
investigated dream-ESP and circadian pineal rhythms 
among young adults finding a significant improvement in 
dream precognition scores at 3 a.m. compared to 8 a.m. 
(Luke, Zychowicz, Richterova, Tjurina, & Polonnikova, 
2010, 2012) with scores in the same direction but non-
significant in a replication study (Luke & Zychowicz, 
2011), providing some tentative support for the notion 
that ESP may be linked to circadian pineal rhythms. 
Roney-Dougal (2001) has also drawn parallels 
between the ostensibly psi-conducive nature of the 
shamanic trance state, psychotic states, psychedelic 
states, and the dream state, which she suggested all 
belong to the same continuum—perhaps somewhat 
akin to Thalbourne’s (1998) concept of transliminality, 
the proclivity for psychological material to cross 
thresholds in or out of consciousness—and that they 
all show suggestive evidence of being regulated by the 
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same neurochemical processes. Recently, the discovery of 
trace amine receptors in the brain for which DMT shows 
greater affinity than does serotonin—its more common 
neuro-amine cousin—has lead to a resurgence of interest 
in endogenous DMT in the mediation of mental health 
(Jacob & Presti, 2005). 
1.3 DMT, near-death, and 
other anomalous experiences
After extensive research investigating the 
phenomenological effects of administering intravenous 
injections of DMT, Strassman (2001) has independently 
hypothesized a role for DMT similar to that suggested 
by Roney-Dougal (2001). Strassman echoed the same 
neurochemical action of the pineal as Roney-Dougal, and 
similarly proffered that psychotic, dream, meditation, 
and mystical states all occur through the overproduction 
of DMT, implicating DMT as a “reality thermostat” 
(Strassman, 2001, p. 327). However, Strassman indicated 
the action of DMT, not β-carbolines, as primary in 
producing these states and alternatively proposed that 
the pineal gland and endogenous DMT are central 
during extraordinary events, such as birth, death, and 
the near-death experience (NDE). 
To support this view Strassman noted that 
the anatomy of the pineal, suspended in cerebrospinal 
fluid outside of the blood-bathed brain, is independent 
enough to resist activation by normal stresses and yet 
is optimally situated to deliver DMT directly to the 
middle brain regions where DMT-sensitive serotonin 
receptors are involved in mood, perception, and thought. 
Furthermore, access to the brain in this way eliminates 
the need for DMT transportation in the blood—where 
it would be broken down by MAO enzymes anyway—
thereby negating the need for a pumping heart for delivery. 
Jacob and Presti (2005) also noted that DMT is virtually 
unique among endogenous neurotransmitters in that it 
is a molecule small enough to have blood-brain barrier 
permeability. That melatonin exerts its influence slowly 
over a period of a day or more, and so does not need the 
pineal’s unique location, further supports the supposed 
postmortem function of DMT. Strassman further 
speculated that the pineal might continue to produce 
postmortem DMT for a few hours. He also noted that 
the NDE has psychedelic and mystical qualities, and that 
the DMT experience often shares the same features as 
an NDE. Some of his DMT study participants reported 
NDEs and death-rebirth experiences, with many others 
reporting a newfound fearlessness of death. However, 
that the participants may have been inadvertently 
primed for these experiences cannot be ruled out because 
they were told in the briefing to expect feelings of death 
or impending death. Nonetheless, independent survey 
research indicates that DMT users sometimes do report 
death-like and near-death-type experiences (Luke & 
Kittenis, 2005).
To Strassman’s (2001) surprise many of the 
participants in his DMT study reported contact with 
sentient beings during the experience, often described as 
elves, dwarves, imps, gremlins, clowns, reptilian beings, 
and aliens, but also as spirits, gods, or just as a presence, 
which was commonly supremely powerful, wise, and 
loving. Such prevalent encounter experiences with 
DMT use (for a review see Luke, 2011b) are seemingly 
so unique and reliable (e.g., Meyer, 1993) as to have 
had the impish characters popularly dubbed the “self-
transforming machine elves” (McKenna, 1991, p. 16), 
and whose tangible reality has been hotly debated by 
other DMT-experience researchers (Carpenter, 2006; 
Kent, 2005, 2010; Luke, in press; Pickover, 2005). 
Strassman suggested that fluctuations in endogenous 
DMT levels were also responsible for the frequent reports 
elsewhere of alien abduction, which share the newfound 
fearlessness of death and visions of energy tunnels, or 
cylinders of light, in common with DMT experiences. 
Following personal experiences with ayahuasca, Severi 
(2003) likewise noted the similarity between NDEs, 
traditional psychedelic-induced shamanic initiations, 
alien abduction experiences, and heightened psychic 
sensitivity, as have previous researchers (e.g., Harvey-
Wilson, 2001; McKenna, 1991; Ring, 1989, 1992). 
However, Barušs (2003) pointed out that, despite the 
similarities, DMT and alien abduction experiences lack 
specific similarities, such as the absence with DMT of the 
classic “grays” (small gray aliens). Nevertheless, Hancock 
(2005), also having experienced DMT and ayahuasca, 
argued that there are substantial similarities between 
aliens and elves, whether induced through DMT or else 
appearing in historic-folkloric legends and testimonies, 
speculating that the latter also have a DMT-induced 
etiology and, adopting the theory proposed by Vallee 
(1969), that these elves of folklore are the prototype 
encounter/abduction experiences. It should be noted 
that few experiencers ever doubt the reality of their 
encounters with either aliens (Mack, 1999) or DMT 
entities (Strassman, 2001), perhaps with the exception 
of Kent (2005, although see Kent, 2010) in this latter 
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category, and most actually consider them to be more 
real than most ordinary experiences. Additionally, like 
alien abduction reports, Strassman notes that his DMT 
study participants reported being probed and having 
things inserted into them by the beings, however, it 
should be noted that this might have been induced by 
the medical nature of his experiments and the use of 
intravenous injections and equipment for monitoring 
vital signs. 
Incidentally, although neither Strassman nor 
other researchers originally pointed this out, it is apparent 
that some of the DMT experiences reported in his study, 
particularly the negative ones, share several features in 
common with sleep paralysis (e.g., see Cheyne, 2001), 
particularly the sense of presence, reports of one’s chest 
being crushed, strange whistling, whining, and whirring 
sounds, and the terrifying paralysis of both body and 
vocal chords (Strassman, 2001). Alien abduction 
experiences and NDEs are also associated with sleep 
paralysis (see Sherwood, 2002), and indeed Strassman 
(2008) later noted the apparent relationship between 
sleep paralysis and DMT experiences, although caution 
has been raised about claiming too many anomalous 
phenomena can be explained by DMT, as this ultimately 
explains nothing, and further phenomenological analysis 
is needed (Luke, 2008), such as that conducted by Cott 
& Rock (2008), although a direct comparison of such 
experiences is needed. Nevertheless, there certainly 
warrants something to research here regarding a DMT 
etiology for sleep paralysis. 
Curiously, experiential reports from research 
programs in the 1950s and 1960s (outlined in Shulgin 
& Shulgin, 1997; Torres & Repke, 2006), indicate that 
the endogenous 5-hydroxy-DMT (bufotenine), a very 
close relative to DMT with similar neurochemistry, 
is seemingly able on occasion to cause feelings of 
constriction in the throat and the crushing of one’s 
chest, as well as anxiety and fear reactions, much 
like sleep paralysis, possibly implicating it as a co-
chemical factor in such experiences, along with DMT. 
Additionally, in South America and the Caribbean 
the entheogenic cohoba snuff is made from one of the 
few traditionally-used plants in which bufotenine is 
active, Piptadenia peregrina, and is used specifically to 
contact spirits (Cohen, 1970; Torres & Repke, 2006), 
perhaps somewhat like the sensed presences of sleep 
paralysis and numerous DMT experiences. However, 
Ott (2001) pointed out that the circulatory crises in 
the earlier bufotenine research were most likely due to 
psychological factors caused by the enforced nature of 
the experiments—conducted as they were on psychiatric 
patients and prisoners with limited consent—because 
such experiences were absent during Ott’s own extensive 
self-experimentation, and nor do indigenous users of 
plants containing bufotenine worry about or report 
respiratory arrest (Torres & Repke, 2006). In any case 
the breathing difficulties associated with sleep paralysis 
may be more to do with the paralysis of conscious bodily 
functions caused by being asleep, and the inability to 
inhale at will. Furthermore, sensed presence, as opposed 
to direct perception of an entity, as often occurs with 
sleep paralysis, may be more common with other 
substances, such as Salvia divinorum (Aardvark, 2002; 
Addy, 2010; Arthur, 2010) (meaning something like 
“diviner’s sage”), although systematic phenomenological 
research is needed. 
In evaluation of the role of the pineal gland and 
endogenous psychedelics in the activation of psi and the 
NDE, it has yet to be shown that psi can be produced 
with these substances under controlled conditions. 
In addition, both psi experiences and NDEs might be 
induced with other psychoactive substances, as shown 
in the following sections, although this criticism has 
been countered by Strassman (2001) with the possibility 
that other psychedelic substances may also stimulate the 
pineal and endogenous DMT by their action. However, 
this proposal is little more than conjecture. Furthermore, 
although there is good reasoning for the hypothesis that 
DMT is made in the human pineal, this is yet to be 
proven and remains speculative, like many of Strassman’s 
and Roney-Dougal’s suppositions at the present time. 
According to Strassman (2001), although the 
lungs, liver, blood, and eye all contain the enzymes 
necessary to convert tryptamine to DMT, the pineal gland 
is especially rich in them and also has high concentrations 
of serotonin ready to convert to tryptamine. So while 
the pineal-DMT hypothesis is currently unproven 
(Hanna, 2010), it is certainly feasible, especially when it 
is considered that the chemical conversion of tryptamine 
to DMT can be demonstrated en vitro. The only attempt 
thus far to support the hypothesis directly has been 
Strassman’s attempt to isolate DMT from 10 human 
pineal glands extracted from cadavers. No DMT was 
detected in the glands; however, neither the bodies nor 
the glands were freshly frozen and any chemicals present 
may have degraded before analysis (Strassman, 2001). 
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Thus far DMT has been found to be naturally 
occurring in the brains of rodents (Kärkkäinen et al., 
2005), and in the highest concentrations in humans 
in the cerebrospinal fluid (for a review, see Barker, 
McIlhenny, & Strassman, 2012), but not the brain, 
let alone the pineal. Furthermore, although the pineal 
contains methyltransferase enzymes, as Strassman 
(2001) indicated, the particular one thought to be 
crucial for en vivo DMT production (indolethylamine 
N-methyltransferase, or simply INMT) has as yet not 
been found in the human brain or pineal gland although, 
curiously, DMT was found in rabbit brain tissue, 
despite the absence of INMT (Kärkkäinen et al., 2005), 
perhaps indicating that INMT is not necessary for the 
production of DMT. Furthermore, McIlhenny (2012) 
pointed out that most INMT mapping research only 
establishes where enzyme translation is occurring, as 
they are based solely on INMT mRNA studies. A recent 
study (Cozzi, Mavlyutov, Thompson, & Ruoho, 2011) 
using a florescent INMT antibody suggests the presence 
of INMT in three Rhesus macaque nervous tissues 
samples, including the pineal gland. Evidence of INMT 
in primate pineal glands indicates better potential for 
Strassman’s human pineal-DMT production hypothesis, 
nevertheless direct support is still lacking. However, 
absence of evidence is not evidence of absence, and the 
pineal gland is difficult to research en vivo and DMT is 
an under-researched substance, particularly in humans. 
DMT is also difficult to detect (Barker et al., 2012) and 
belongs to the most controlled category of drugs in most 
countries, so, currently, the jury remains out on the 
pineal-DMT hypothesis. 
Overall, despite their incompleteness, the 
pineal/β-carboline/DMT models of psi and NDE do 
offer unique neurochemical perspectives on paranormal 
experience around which further research can be framed. 
Additionally, although neither author has speculated 
on the others’ ideas, their models are not incompatible 
with each other; however, they may begin to answer 
the question of why such visionary molecules as DMT 
are made within humans at all. For a further discussion 
of DMT, brain action and anomalous phenomena, see 
Luke (2011b). 
1.4 Ketamine and NDEs 
A proliferation of reported cases of NDEs with 
the use of ketamine (Jansen, 1997a, 1999, 2001) and the 
similarity of aspects of the ketamine experience to that 
of the NDE (Morse, Venecia, & Milstein, 1989; Rogo, 
1984)—despite Morse’s (1997) later contentions that the 
evidence for this is weak—has led to the development of 
a neurochemical model of NDE based upon the action 
of this psychoactive substance (Jansen, 1990, 1997a, 
2001). A dissociative anesthetic—also reported to induce 
experiences of telepathy, precognition, clairvoyance, 
psychokinesis, communication with the dead, kundalini 
experiences and an increase in synchronicities (Case, 
2003; Jansen, 2001; Luke & Kittenis, 2005; Wyllie, 
1981)—ketamine acts by binding to the phencyclidine 
(PCP) site of the N-methyl-D-aspartate (NMDA) 
receptor, blocking the action of the neurotransmitter 
glutamate. Jansen indicated that potentially life-
threatening circumstances (e.g., hypoxia, ischemia, 
hypoglycemia, temporal lobe epilepsy) can initiate a 
glutamate flood, which results in neurotoxicity through 
the over-activation of the NMDA receptors (for further 
details, see Smythies, 2011). This NDE trigger may be 
accompanied by a flood of neuroprotective agents that 
also bind to the NMDA receptors preventing damage, 
in much the same way as ketamine. Like Grinspoon and 
Bakalar’s (1979) speculation that the brain synthesizes a 
chemical similar to ketamine in times of stress, Jansen 
proposed that “endopsychosins,” which bind to the same 
receptor site as ketamine, would be discovered as the 
neuroprotective agents that cause an ASC, like that of 
ketamine, termed the NDE. 
Although parsimonious, Jansen’s (1997a) 
ketamine model of NDE has been both duly criticized 
and well defended. It has been argued that unlike 
NDEs, ketamine trips frequently induce fear (Strassman, 
1997) and are not considered “real” (Fenwick, 1997). 
However, as Jansen (1977b) likewise contested, it is 
becoming increasingly recognized now that NDEs 
are also commonly reported to be distressing or 
traumatic (Atwater, 1994; Montanelli & Parra, 2000) 
and, furthermore, ketamine experiences are also more 
often than not reported to induce a sense of peace and 
pleasantness (Corazza, 2008; Luke, 2007). In support of 
the perceived reality of the ketamine experience, there are 
documented accounts of people who have had an NDE 
and then later a ketamine experience, and who reported 
the experiences being the same (Jansen, 2001). In support 
of this, Grof (1994) found that several cancer patients 
had NDEs during psychedelic therapy (most likely with 
LSD) that were very similar to later spontaneous NDEs. 
In further criticism of Jansen’s model, it has 
been argued (Fenwick, 1997; Greyson, 2000) that the 
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clarity and clear memory of the NDE experience is 
not consistent with cerebral dysfunction. However, it 
is arguable that Jansen’s model does not stipulate the 
necessity of cerebral dysfunction for a NDE, merely the 
threat, or even just the perceived threat of it, and Jansen 
(1997b, p. 87) pointed out “there is no reason to suspect 
that the NDE mechanism would never be activated 
spontaneously.” Furthermore, Jansen (1997b) regarded 
clarity of consciousness as a nebulous term in the 
discussion of altered states, as the term is loaded towards 
the ordinary state of consciousness. Some researchers (e.g., 
Greyson, 2000; Smythies, 2011) have further contested 
that, despite the possibility that the endogenous peptide 
alpha-endopsychosin is a candidate, no endopsychosins 
have yet been identified or proven to exist, and Jansen 
(2001) conceded that this may initially have been a 
false lead and has suggested a number of alternative 
endogenous NMDA antagonists as candidates: N-acetyl-
aspartyl-glutamate, kynurenic acid and magnesium, all 
of which protect brain cells from excito-toxic damage 
(Jansen, 2004). Nevertheless, Thomas (2004), following 
Jansen in his search, has identified technical flaws with 
these speculated endogenous “NDE-ogens” and has 
instead proposed the neuromodulator agmatine as the 
most likely candidate. The debate continues.
In further criticism of the model, Parker (2001) 
noted that one-drug/one-experience theories were aban-
doned in the 1970s and that, along with Greyson (2000), 
he further noted that ketamine appears to have multiple 
effects in the brain and multiple experiential features, 
some of which include those of the NDE. Jansen 
(1997b) earlier countered this latter criticism with the 
proposal that factors of set and setting are paramount 
in determining experience with all ASCs, be they NDEs 
or ketamine-induced states, so experiences are expected 
to vary. Parker (2001), like Siegel (1980), added that 
other drugs also produce features of the NDE, although 
Jansen (1997b) has asserted that these NDE-features 
are typical with ketamine but are not typical with other 
drugs, except for PCP and ibogaine (Bianchi, 1997; 
Jansen, 2001) which are NMDA antagonists (or more 
specifically called NMDA-PCP receptor blockers). 
However, in support of Parker’s (2001) criticism, 
Roll and Montagno (1985) have noted the similarity 
between NDEs and LSD experiences, as reported by 
Grof (1994). Reports of NDE also occur with the use 
of other dissociatives, like dextromethorphan (DXM)
(White, 1997), and carbogen (Meduna, 1950), as well 
as with high doses of hashish (Siegel & Hirschman, 
1984), and tryptamines like 5-MeO-DMT (Shulgin 
& Shulgin, 1997) and the ayahuasca (meaning “the 
vine of the dead”) derivative, DMT (Strassman, 2001). 
Yet, Strassman (2001) did not find Jansen’s model 
incompatible with his own DMT model of NDE, but 
rather asked why a neuroprotective agent like ketamine 
should also be psychedelic as there is no obvious benefit 
to the near-death visionary experience, other than 
enabling consciousness to have awareness of its departure 
from the body. 
Recently, electrophysiology and receptor 
studies have revealed that both NMDA antagonists, 
such as ketamine, and classic hallucinogens, such as 
LSD, may actually enhance glutamatergic transmission 
via non-NMDA receptors in the frontal cortex. This 
may indicate a common mode of chemical action in 
the brain responsible for such similar experiences with 
these divergent molecules, though further investigation 
is required (Vollenweider, 2004). Given the similarities 
between NDEs, ketamine experiences, and other drug 
experiences, Rogo (1984) proposed that the NDE-like 
effects of ketamine are more often interpreted as NDEs 
because it has so often been used in a medical setting, 
further suggesting that ketamine-induced NDEs are less 
prevalent with recreational use than with anesthetic use, 
though this has not been systematically investigated to 
my knowledge. 
To the author’s knowledge, the only systematic 
investigation of the ketamine hypothesis, besides Jansen 
(2001), is that of Corazza (2008), who compared 36 cases 
of apparent NDEs induced by ketamine with 36 cases 
of NDEs reportedly caused by a cardiac arrest or other 
life threatening circumstances. Both groups showed a 
high degree of similarity in certain experiential features, 
with a roughly equal prevalence among the groups 
of experiences involving altered perceptions of time, 
speeded up visions, and the occurrence of ESP (25%), 
but the ketamine group were more likely to report unity 
with the universe, and the cardiac groups were more 
likely to report dissociation from the body, visions of 
light, and encounters with deceased or religious beings. 
However, Corazza asserted that the evidence indicates 
that NDEs can be induced through ketamine, although 
they may not be identical to those occurring naturally. 
The study is not without its limitations; 
however, as outlined by Luke (2009), as the ketamine 
participants were recruited on the premise that they felt 
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that they had had an NDE on ketamine, which Jansen 
(2001) reported only occur to about 12% of ketamine 
users. Furthermore, it is unclear if the respondents are 
describing a specific ketamine experience or an experience 
more generally, as most of the respondents had taken 
ketamine between 10 and 2000 times, though a similar 
number of cardiac arrest experiences is very unlikely 
for the comparison group. Nevertheless, Corazza and 
Schifano (2010) acknowledged the limitation that their 
findings are based on a self-selected, nonrandomized, 
limited size sample. Subsequently, ketamine can at best 
be thought of as an occasional NDE trigger or mimic, 
but is not a wholly repeatable or reliable source of NDEs 
(Luke, 2009). Nevertheless, cardiac arrest and the 
experience that ketamine invokes appear to be similar 
enough to genuine NDEs that leading consciousness 
researchers Hameroff and Chopra (2010) have called 
for its use in prolonging end of life brain activity (by 
delaying neurotoxicity) to allow terminally ill patients to 
have more conscious deaths.  
More recently, having first researched the 
parapsychological potential of psychedelics in the 1940s, 
Smythies (2011) identified several apparent flaws with 
Jansen’s K-NDE model. First, an NMDA-antagonist 
model of NDE is too general because the glutamate 
receptors can be found in all regions of the brain and 
yet the NDE phenomena suggest the activation of only 
specific brain regions, and furthermore ketamine does 
not appear to produce global brain NMDA-antagonism 
(although this latter point may argue against the first). 
Second, ketamine, Smythies argued, cannot actually 
stimulate the action potential of the neurons it binds 
to, but rather affects the modulation of the strength 
and number of synapses (i.e., the neuroplasticity), so it 
cannot immediately affect the brain regions required to 
stimulate the NDE. This second argument, however, 
seems somewhat contradicted by the phenomenological 
evidence that suggests that ketamine can in fact stimulate 
NDE-like phenomena and so presumably does activate 
the appropriate brain regions, at least indirectly. 
Finally, Smythies (2011), contested that if the 
NMDA-antagonism explanation for NDEs were true, 
one would expect to see a relationship between NDEs 
and grand mal epilepsy—during which massive cerebral 
glutamate overload occurs. However, according to 
Smythies, the relationship is only apparently reported by 
one study (Britton & Bootzin, 2004), and is in any case 
weaker than the relationship between epilepsy symptoms 
and disturbed sleep patterns, although, in argument 
against Smythies, this weaker relationship may be 
accounted for by the infrequent occurrence of NDEs 
relative to sleep disturbances. Furthermore, counter 
to Smythies’ conjecture, several other researchers have 
speculated about the link between NDEs and temporal 
lobe epilepsy, drawing parallels (Blanke & Dieguez, 
2009; Jansen, 2001; Morse, Venecia, & Milstein, 1989; 
Neppe, 1989; Persinger & Makarec, 1987; Saavedra-
Aguilar & Gómez-Jeria, 1989), although admittedly the 
NDE-epilepsy link is incomplete (Neppe, 1989), and 
epilepsy might best be thought of as one of several possible 
NDE triggers, as Jansen (1997a) originally proposed, 
rather than an explanation for NDEs. Ultimately, 
Smythies (2011) proposed that the excitatory NMDA 
receptor system, which runs continuously even while 
asleep, actually is the Bergson brain filter mechanism 
(discussed earlier in section 1.1) that ordinarily prevents 
people from experiencing what Aldous Huxley (1954, 
p. 11) called “Mind at Large”: mystical and paranormal 
consciousness (i.e., an NDE). Consequently, Smythies 
asserted that NDMA antagonism, such as via ketamine or 
a natural NDE, bypasses the brain’s natural filter action, 
leading to all manner of paranormal and transpersonal 
experiences. Much as Smythies should be applauded for 
morphing the two theories together, the same might be 
said for psychedelically induced serotonergic action as 
for glutamatergic action, so in effect this says little more 
than what Huxley originally proposed and what is now 
known about psychedelic neurochemistry (see section 
1.1).
Overall, despite over simplification and 
generalization, the ketamine model of NDE offers the 
most complete neurochemical explanation of the NDE 
so far and, as with the DMT model, does not necessarily 
assume a materialist reductionism to explain the data 
—unlike Siegel (1980) for example—although some 
commentators (e.g., Sakellarios, 2005) have erroneously 
assumed that it does. Furthermore, the model can be 
easily tested and refined. For instance, there is evidence to 
suggest that the non-competitive antagonism at the non-
glycine site of the NMDA receptor in particular is linked 
to the event of dissociative anesthesia and altered sensory 
perceptions that are familiar to ketamine. This would 
indicate that relatively novel substances like HA-966 
(1-hydroxy-3-amino-pyrrolidone-2), which acts in this 
particular neurochemical manner (Bonta, 2004), could 
induce NDEs in blind conditions comparable to those 
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occurring ordinarily, though this remains to be seen. In 
research with monkeys, HA-966 induced EEG patterns 
characteristic of sleep despite the animals remaining 
completely alert, which may be related to Jansen’s (2004) 
observation that the same 60% of the population that do 
not recall their dreams also do not recall their ketamine 
experiences during anesthesia, a proportion apparently 
equivalent to the number of people who do not report 
having had some kind of NDE. Alternatively, in order 
to test the K-NDE theory, it has been suggested to 
administer ketamine to those who have had a natural 
NDE and compare the two (Kolp et al., 2007). Assuming 
ketamine NDEs to be genuine, ultimately, however, the 
question remains of whether chemically induced NDEs 
utilize alternative pathways or the actual NDE pathway 
(Fracasso & Friedman, 2011).
Bringing personal observations (Luke, 2005) to 
the K-NDE debate, it seems apparent that the degree of 
general anesthesia induced by ketamine is relative to one’s 
motor control ability and what Grosso (1976) identified 
as the degree of being out-of-body: Factors that are more 
pronounced with the positive S-isomer of ketamine 
rather than the negative isomer (Domino & Warner, 
2010), further indicating how entwined these effects 
are, specific as they are to just one ketamine molecule 
type. Such relationships between sensory and motor 
impairment and reported body image have elsewhere 
been found with local anesthesia (Paqueron et al., 2003), 
though obviously not full blown OBEs. Retuning to the 
personal observations, in repeated ketamine experiences 
I observed that the initial stages of anesthesia and out-
of-body-ness are accompanied by increasing difficulty 
in controlling one’s body and a growing sense of body 
dysmorphia, in a non-clinical sense, in that part of 
one’s body may appear longer (macrosomatognosia) or 
shorter (microsomatognosia), as described by Frederiks 
(1963). For example, on one occasion I recall being 
unable to successfully maneuver out of the door because 
my legs appeared to be the approximate distance of 
an entire football pitch away. It is observed that the 
relatively changing gradation in increased anesthesia, 
body dysmorphia and motor control continues, with a 
sufficient dosage, as the trip intensifies towards a full-
blown out-of-body experience, total anesthesia, and 
ultimately no motor control.
Indeed, while some K-OBEs are accompanied 
by autoscopy, even awareness of one’s body can disappear 
at the peak of a high dose ketamine experience, even to 
the point of not realizing one actually has a body but 
instead  just experiencing the present as a single point of 
consciousness and nothing more. On one such occasion 
I was seemingly privileged to a view of earth from space 
and yet I did not even know who or what I was, let 
alone that I was human and apparently had a body. This 
relatively changing relationship between anesthesia, 
motor control, out-of-body-ness, and even body-
ownership-awareness is apparent on both entering and 
exiting the ketamine experience, although seemingly 
more so in exiting (although in reverse), as the entrance to 
a ketamine experience can often be abrupt, with a swift 
and intense onset, whereas the departure is more gradual. 
Such first-person psychonautics can report a good deal 
about both psychedelic states, especially ketamine states 
(Newcombe, 2008), and parapsychological phenomena 
(Luke, 2011c) and such methods are witnessing 
somewhat of a revival after a long hiatus since the era 
of William James’ (1902) classic experimentation with 
nitrous oxide, another NDMA antagonist. Survey 
research also shows that ketamine induces OBEs and 
autoscopy far more often than other (non-anesthetic) 
psychedelics (Wilkins, Girard, & Cheyne, 2011), as had 
been previously speculated (Luke & Kittenis, 2005), the 
question remains of why anesthesia should accompany 
an OBE/NDE: Does the anesthesia cause the perception 
of being out of one’s body, and therefore leads to a 
feeling of dying or of having died, or does the near-death 
experience provoke an OBE and subsequent anesthesia 
as a defense against likely pain? Observing the ketamine 
experience from the recipient’s perspective, it appears 
that the anesthesia occurs because one’s consciousness 
is no longer connected to one’s body, and certainly the 
OBE and anesthesia are intimately connected, but why 
and how deserve further investigation and may shed 
light on the neurobiological factors of OBEs and NDEs. 
1.5 Dopamine and paranormal 
beliefs and experiences. 
Taking a purely materialist reductionist view 
of paranormal experiences by attempting to account for 
them exclusively in terms of beliefs arising from faulty 
cognitions—what Irwin (2009) called the cognitive 
deficits hypothesis—a loose neurobiological model for 
the explanation of paranormal beliefs has arisen that 
posits the dopamine neurotransmitter system as the 
primary facilitator. Put forward by Krummenacher 
and colleagues (Krummenacher, Brugger, Fahti, 
& Mohr, 2002; Krummenacher, Mohr, Haker, & 
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Brugger, 2009) the theory suggests that, although 
activity of the endogenous neurotransmitter dopamine 
is classically implicated in enhancing cognitive and 
perceptual decisions by improving the signal to 
noise ratio of neuronal transmission, paradoxically, 
hyperdopaminergic activity is associated with psychotic 
symptoms, schizophrenia and even schizotypy (for a 
brief review, see Krummenacher et al., 2009), and so 
excess dopamine may be accountable for delusional 
thinking stemming from an increased tendency to 
find patterns in apparently random data—what the 
psychiatrist Klaus Conrad (1958) called apophenia. 
According to Brugger and colleagues (e.g., Pizzagalli, 
Lehmann, & Brugger, 2001) paranormal believers—
and so most likely paranormal experiencers too—have 
been shown to be more inclined towards apophenia than 
skeptics, thereby accounting for the increased creativity 
apparently associated with paranormal thinking and its 
similarity to some psychotic symptoms: a combination 
of creative and delusional dimensions being indicative of 
the positive phenomenology of schizotypy (Eckblad & 
Chapman, 1983). 
Direct research into what might be most 
accurately called the hyperdopaminergia-apophenia 
hypothesis is somewhat limited at this time, consisting 
of only two studies, with somewhat mixed results. 
The first study (Raz, Hines, Fossella, & Castro, 2008) 
attempted to relate paranormal belief as a phenotype 
to hyperdopaminergia as a genotype via what Raz et 
al. (2008) called the “COMT dopaminergic gene” (p. 
1336), building on preliminary findings in behavioral 
apophenia dopamine research by Krummenacher et 
al. (2002) and studies associating schizotypy with 
dopaminergic genes (e.g., Avramopoulos et al., 2002). 
COMT (Catechol-O-methyltransferase) is an enzyme 
that degrades catecholamines such as dopamine, and 
the COMT protein is encoded by the COMT gene. 
Utilizing questionnaire measures of paranormal belief, 
107 psychology students were genetically screened for 
three COMT allelic forms, successfully identifying 
approximately one quarter of the sample with high 
COMT activity, a quarter with low activity, and half 
with intermediate activity. However, failing to support 
the hyperdopaminergia-apophenia hypothesis those 
with decreased COMT activity, and hence greater 
hyperdopaminergia, reported no more paranormal 
beliefs, abilities or experiences than the higher COMT 
activity participants. Undeterred, Raz et al. (2008) 
pointed to the observation that attempting to unravel 
links between single gene polymorphisms that influence 
neurochemical function, and consequently individual 
differences in cognitive function, may be difficult when 
using distal phenotypes such as questionnaire measures, 
and that more proximal measures like brain imaging 
might be more promising. Indeed behavioral genetics is 
in a state of epistemological crisis after the lack of hard 
findings from the recently completed Human Genome 
Project (e.g., see Maher, 2008), so it may well be too soon 
to expect good data relating paranormal beliefs to genes, 
particularly single genes, even if they are related.  
The second study, by Krummenacher et al. 
(2009), sampled 20 paranormal believers and 20 
paranormal non-believers and administered levodopa 
—an active precursor to dopamine in the brain—in a 
randomized placebo controlled between-subjects study. 
Participants were given two signal detection tasks, 
one with words (tapping left hemisphere processes) 
and one with faces (right hemisphere), that presented 
either word/non-word or face/non-face stimulus pairs 
tachistoscopically for just 140 milliseconds. Participant 
responses were assessed for both their tendency to make 
correct guesses relative to incorrect ones, their sensitivity 
index (d’), and their tendency to respond with a positive 
or negative bias, their response tendency (C), both 
measures being independent of each other. Findings 
indicate that skeptics had significantly greater sensitivity 
to signal detection than believers in the placebo condition 
but, contrary to expectations, increased dopamine lead 
to a significant decrease in sensitivity in skeptics and had 
no effect on believers. These findings challenge the view 
that dopamine generally assists in signal detection, and 
Krummenacher et al. (2009) suggested that the opposite 
may actually be true in some cases, especially with 
presumed hypodominergic individuals (i.e., skeptics). 
Additionally, the authors argued that the lack of change 
in sensitivity in believers administered levodopa may be 
due to a plateau effect caused by high cerebral dopamine 
baseline levels; however, such a suggestion is somewhat 
post hoc and, even if it were true, the authors do not 
comment on why the dopamine-enhanced skeptics had 
lower sensitivity (i.e., greater sensory apophenia) than 
either believer group. 
Whereas the sensitivity measure findings are 
puzzling, the response bias measure results are somewhat 
more straightforward, in the control scenario at least. As 
was expected, in the placebo condition believers had a 
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greater tendency to respond in the affirmative (favoring 
a Type I error strategy), whereas skeptics had a greater 
tendency to respond in the negative (favoring a Type 
II error strategy), the difference between the groups 
being significant. However, against expectation, in the 
levodopa condition these tendencies in each group were 
diminished so that there was no significant difference 
between skeptics and believers, although the trend 
remained. Specifically, compared to their placebo 
controls, dopamine-enhanced believers were more 
cautious of making false positive decisions (i.e., more 
conservative), and skeptics were less prone to make false 
negative decisions (i.e., more liberal, so that in effect both 
believer groups were less polarized in their responses. 
Contrary to the linear dopamine-apophenia relationship 
originally proposed, these results may indicate differing 
baseline dopaminergic activity in skeptics and believers 
and the possibility that there is a non-linear relationship 
between task and dopamine levels, perhaps an inverted 
U-shape, possibly modulated by individual differences 
in belief. However, these findings should be replicated 
first and more direct measures of baseline dopamine 
(e.g., spinal dopamine metabolic marker assay) should be 
made before these findings and post hoc interpretations 
are given much weight. Furthermore, as the authors 
noted, use of a between- rather than within-subjects 
design is far from ideal, leaving too much faith in the 
randomization of the small groups and no certainty in 
equivalence of baselines in dopamine responsivity and 
behavioral performance, and so further studies would 
benefit from a cross-over design. 
Aside from the current lack of research on 
the hyperdopaminergia-apophenia hypothesis and the 
somewhat confusing mixed results, this line of research 
seems worthwhile pursuing further, although it suffers 
from additional limitations. One is that it aims to 
boil down paranormal experiences to misperceptions 
and misjudgments of the pattern recognition type, 
which, even if one allows for the fact that the authors 
a priori preclude the possibility of genuine paranormal 
phenomena, this approach does not account for the 
swathe of other cognitive deficits that are also given to 
account for paranormal beliefs, such as poor judgments 
of probability and randomness, egocentric bias, selective 
remembering, confirmation bias, and more (Brugger & 
Mohr, 2008). Indeed a study investigating probability 
inferences in those under the influence of ketamine, 
versus matched controls and schizophrenic patients, 
shows that the ketamine group were no different from 
the placebo group, whereas the patients were shown 
to exhibit a jump-to-conclusions response concerning 
probability inferences (Evans et al., 2012). Although 
ketamine is primarily an NMDA-antagonist, it also 
has direct effects on dopamine receptors (e.g., Kapur & 
Seeman, 2002), and so the lack of probability inference 
effect with ketamine does not complement a dopamine 
explanation for paranormal experiences within the 
cognitive deficits paradigm. Other psychological factors 
supposedly related to paranormal experiences, such 
as the propensity for false memories, also show no 
relationship with self-reported recreational drug use 
generally (Wilson & French, 2006). 
So in this respect the dopaminergic approach 
does not currently incorporate many of the multitudinous 
psychological explanations for paranormal beliefs and 
experiences. Furthermore, the wealth of evidence, to 
follow, relating increased paranormal experience—and 
to some extent experimentally controlled production of 
ESP—to the ingestion of psychedelic substances does 
not particularly support a dopamine-based theory of 
paranormality either, as dopamine activation is neither 
primary nor ubiquitous with psychedelic substances. 
Typically, classic tryptamine psychedelics (such as LSD 
and psilocybin) are thought to exert their effects via 
serotonin activation, particularly via the 5-HT2A receptor 
subtype (Lee & Roth, 2012). Nevertheless, it is thought 
that 5-HT2A receptor stimulation can activate dopamine 
release (Diaz-Mataix et al., 2005), and Previc (2011) 
asserted that all the various psychedelic neurochemical 
pathways to “altered states of consciousness with 
distorted reality” (p. 43) ultimately lead to elevated levels 
of dopamine in the brain, although such reasoning rather 
ablates the intricate nuances of psychopharmacology and 
disregards primary neurochemical pathway activation 
as in any way important. Furthermore, although some 
psychedelic substances (e.g., LSD, psilocin, DMT) 
do have relatively high affinities for certain dopamine 
receptors (Ray, 2010), dopamine is rarely considered to 
be a primary neurotransmitter site for psychedelic effects. 
Indeed, the primarily dopaminergic recreational drugs, 
such as amphetamine and cocaine, have been found to 
be either unrelated or negatively related to paranormal 
experiences and beliefs (for a review see Luke, 2008b; 
and see section on survey data, to follow), contradicting 
the dopamine-paranormal belief/experience hypothesis. 
Indeed, if Previc were right about psychedelics exerting 
International Journal of Transpersonal Studies 111Psychoactive Substances and Paranormal 
their effects via the dopamine system, then one would 
expect amphetamine and cocaine to be psychedelic too, 
which they are not. 
Furthermore there are numerous psychedelics 
strongly associated with paranormal experiences that do 
not have dopaminergic action, such as the k-opioid agonist 
salvinorin A (Ray, 2010) and anticholinergic agents like 
scopolamine and hyoscyamine—which are found in 
nightshade family plants like datura (Katzung, Masters 
& Trevor, 2012). Overall—with scant direct research, 
mixed and complex findings, and poor generalizability of 
the hypothesis to a) other psychological explanations and 
b) most of the psychedelic-parapsychology literature—at 
the present time, Krummenacher, Brugger, Mohr, and 
colleagues’ (Krummenacher et al., 2002; Krummenacher 
et al., 2009) dopamine-apophenia conjecture remains 
very much rudimentary and unsupported.
1.6 Overview of psychedelic/neuro-chemical 
models of paranormal experience. 
The preceding sections outline five neurochemical 
models germane to explaining psychic experiences, 
namely the brain as filter, β-carboline and tryptamine, 
DMT, ketamine and, finally, dopamine models. Aside 
from the latter, all of these models draw upon the action 
of psychedelic substances in particular and remain open 
to the possibility that psi and other so-called paranormal 
phenomena may be genuine. It should be noted, 
however, that no one psychedelic model may ultimately 
be the correct one, as psychedelics may work in many 
ways (e.g., dissociatives are both NMDA antagonists, as 
well as mu-opioid agonists); nevertheless these models 
provide important avenues for future research and 
begin to help develop more complete neurobiological 
models of apparent paranormal cognition or merely 
paranormal belief, and, indeed, more complete models 
of consciousness itself. The importance of understanding 
the apparent paranormal effects of psychedelics is clear 
and the evidence in support of this relationship is next 
reviewed and evaluated. 
 
2. Field Reports of Paranormal Phenomena
2.1 Anthropological and Historical Reports
Despite apparent prejudices by anthropologists 
against reporting such phenomena traditionally 
(Winkelman, 1983), the anthropological and ethno-
botanical literature remains replete with examples of 
ostensibly paranormal phenomena occurring with the 
traditional use of psychoactive plants. Commonly these 
plants are taken in ritual context for the express purpose 
of accessing altered states conducive to clairvoyance, 
precognition, telepathy, out-of-body travel, psychic 
diagnosis, psychic healing, and spirit communication, 
which provoked the mycologist Wasson (1964) to 
label them as the keys to extra-sensory perception. 
Archaeological evidence suggests such practices have 
existed the world over for millennia (see Devereux, 1997). 
However, the paranormal effects of particular plants are 
not necessarily arbitrary. Shamans who use the ayahuasca 
brew in Amazonia report having control over whichever 
particular paranormal function the brew elicits through 
the discerning use of psychoactive admixtures that may 
“make you travel, make you see” or “teach you to heal” 
(Andritsky, 1989, p. 78). Indeed, when the harmala 
alkaloid harmine, the first psychoactive compound 
isolated from the ayahuasca decoction, was discovered 
by Guillermo Fischer Cárdenas in 1923 it was named 
“telepathine” (Beyer, 2009) because of its apparent 
psychical properties, as reported by Zerda Bayon (1912). 
Zerda Bayon illustrated this with the case of Colonel 
Morales who, after ingesting ayahuasca, beheld a vision 
of his dead father and his sick sister. About one month 
later he received the same news by messenger. It seems 
unlikely that the news could have arrived first by non-
paranormal means, as the group was deep in the jungle 
15 days’ travel from the nearest communications outpost. 
Clairvoyant states induced with the harmala 
alkaloid-containing Perganum harmala shrub in Morroco 
have also been reported (Rudgley, 2000). Additionally, 
there are many more accounts of such apparent ESP 
with ayahuasca reported in Luna and White’s (2000) 
anthology of classic ayahuasca experiences, as well as 
elsewhere (e.g., Beyer, 2009; Bianchi, 1994; Dobkin 
de Rios & Rumrrill, 2008; Gorman, 1992; Kensinger, 
1978; McGovern, 1927; Shanon, 2002; Weil, Metzner, 
& Leary, 1965; Wilson, 1949). Typically, the earliest 
reports from explorers and anthropologists of the 
Upper Amazon were of either OBEs or experiences 
of someone discovering via visions that some distant 
person known to them, usually a relative, had just died 
(Luke, 2010a). In addition, Naranjo (1967, 1973) gave 
harmaline to 30 naïve urban elite Chilean participants 
who inexplicably reported the same images of snakes 
and jaguars, or big cats, as are commonly reported in 
traditional South American ayahuasca visions (Naranjo, 
1987; Shanon, 2002). Visions of jaguars and snakes with 
harmaline have also been reported elsewhere (Shulgin 
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& Shulgin, 1997) and one second-hand story from late 
sixties Haight-Ashbury (the temporal-spatial epicenter of 
psychedelic counter culture) proffered that someone once 
experimented giving ayahuasca to Eskimos and, devoid 
of the cultural milieu typical of ayahuasca use, they still 
saw huge cats in their visions, although it is unlikely that 
this research ever took place (Weil, 1980). Furthermore 
some of the participants in Naranjo’s study were 
convinced they had seen these images by traveling out-of-
body in time and space. Ott (1993) noted, however, that 
harmaline only occurs in minimal quantities in tested 
ayahuasca decoctions and so cannot be accountable 
for the psychoactive effects of the brew. Nevertheless, 
Strassman (2001) found that administering DMT (the 
most psychoactive constituent of ayahuasca) induced 
a similar certainty of space-time travel and resulted 
in the inordinately frequent occurrence of images of 
DNA, an image which Narby (1998) found commonly 
featured in the ayahuasca healing visions of Amazonian 
shamans, but was most often represented by snakes. It 
has recently been suggested, amid some controversy, that 
the geneticist Francis Crick was under the influence of 
LSD when he had a vision of the double helix structure 
of DNA in 1953, a discovery for which he was awarded 
the Nobel Prize (Rees, 2004). 
Prior to this news report, which came after 
Crick’s death, the anthropologist Narby (2000) took 
three molecular biologists to the Peruvian Amazon 
for their first visit there and for their first encounter 
with ayahuasca. The two female biologists both had 
encounters with plant teachers whom they perceived 
as independent sentient entities, and all three scientists 
received valuable information from their visions that 
helped inform their research, and which ultimately 
changed their world view. For instance, “the American 
biologist, who normally worked on deciphering the 
human genome, said she saw a chromosome from the 
perspective of a protein flying above a long strand of 
DNA” (Narby, 2000, p. 302). Similarly, the biochemist, 
Kary Mullis, who received the Nobel Prize for inventing 
the polymerase chain reaction (PCR) that significantly 
advanced DNA research, said that taking LSD had been 
invaluable in helping him experience the mental imagery 
that allowed him to visualize sitting on a DNA molecule 
to watch the polymerase go by (Mullis, 1998). 
Further reports of the ritual use of psychoactive 
plants for the induction of paranormal abilities are 
commonplace among indigenous peoples from every 
inhabited continent. These range from the use of pituri 
(Duboisia hopwoodii) in Australia (Australian Institute 
of Parapsychological Research, 2004) to the use of 
San Pedro cacti (Trichocereus pachanoi) in Peru (Luke, 
2012a; Sharon, 1990) and peyote cacti (Lophophora 
Williamsii) in Mexico (Slotkin, 1956), Amanita muscaria 
mushrooms by the Ojibwa in Canada (Wasson, 1979) as 
well as suburban Muscovites and Siberian tribes-people 
in Russia (Ostrander & Schroeder, 1997; Wasson & 
Wasson, 1957), the use of datura among the Chumash 
of California (Driver, 1969), and the use of Psilocybe 
mushrooms (Stamets, 1996; Wasson, 1962) and Salvia 
divinorum by Mazatecs in Mexico (Soutar, 2001) to name 
but a few. Indeed, anthropologist Dobkin de Rios (1984, 
p. 60) has suggested that “the single most important 
function of plant hallucinogens in the Amazon area is 
to divine the future.” Efforts to document the diversity 
of these traditional “shamanic” plants indicate there 
are about 100 distinct genera, let alone species, of such 
traditional plants that are reported to induce visionary 
states and are used ethnomedically (Schultes & 
Hofmann, 1992), with new ethnobotanical discoveries 
continually being made. However, few parapsychologists 
have conducted research with these plants or their users 
in their traditional environment, although with Wasson, 
Puharich (1959) attempted a remote viewing experiment 
with the Psilocybe-using Mazatecs in Mexico in 1955, 
but the experiment was aborted when instead Wasson 
and his co-expeditioner, Richardson, became the first 
researchers to be initiated into the mushroom cult. 
Nevertheless, Richardson (1990) reported personally 
having had an apparently precognitive vision, during 
what is documented as the first non-indigenous Psilocybe 
genus (i.e., “magic”) mushroom trip. 
A cross-cultural taxonomical study of 
shamans, shaman-healers, healers, and mediums, posits 
that, although these groups share many of the same 
characteristics, there is a clear division between those 
who do, and those who do not, use psychoactive plants 
and the differing paranormal activities they perform 
(Winkelman, 1989). Levine (1968) credited the botanist 
Schultes with the suggestion that the prevalence 
of vision-inducing plants among the herbarium of 
“primitive” societies is based upon a differing concept 
of illness, which has spiritual rather than physical 
causes. Contrary to Schultes, Winkelman suggested 
that the difference in the use of hallucinogens was due 
to cultural and developmental variances. Shamans from 
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hunting and gathering societies and shaman-healers 
from agricultural subsistence societies both frequently 
use hallucinogens for the purposes of healing, divination, 
hunting-magic, and malevolent acts, whereas healers 
and mediums from sedentary and politically integrated 
societies as well as agricultural subsistence societies, do 
not use hallucinogens to access their altered states, which 
they use for healing and divination only.
Yet it appears that these cultural differences 
have occurred only recently in the developed world, as 
it has been suggested that the ancient Greek oracles, 
including the Pythia of Delphi—the seeresses that 
anteceded the divinatory Goddess Python—also used 
the solanaceae family of psychedelic plants (henbane, 
belladonna, mandrake, and datura) for divination 
(Masters & Houston, 1966; Parker, 1975; von Bibra, 
1855/1994). Indeed the ancient Greek name for 
henbane was “pythonian” (Rudgley, 2000). It is also 
well documented historically that Northern European 
witches also utilized these plants for psychic purposes 
(see Andrews, 1997; Rudgley, 2000). Indeed, similarly 
to the Greeks, the Northern Europeans gave the name 
“alruna” to their visionary seeresses, in common with 
the German name for mandrake, “alraune,” both of 
which stem from “rune,” the Germanic divinatory letter 
system (Müller-Ebeling, Rätsch, & Storl, 2003). No 
doubt, the traditional Northern European practice of 
pharmacologically accessing visionary states all but died 
out with the witches during the Inquisition, between the 
fourteenth and seventeenth centuries (Grob & Harman, 
1995). It is probable that a combination of changing 
concepts of illness, the development of a sedentary, 
politically integrated society, and the influence of the 
Inquisition or colonization were responsible for the 
virtual disappearance of the traditional indigenous use of 
psychoactive plants for paranormal purposes in Europe 
and North America. 
At the end of the 19th century, pioneering 
psychological explorers in the West rediscovered the 
vision-inducing qualities of novel plant substances, such 
as mescaline (Ellis, 1898), whereas others explored new 
synthetic visionary chemicals like nitrous oxide (James, 
1902), with some early psychical researchers dabbling in 
both (Dunbar, 1905). By the middle of the 20th century 
the Swiss chemist Albert Hofmann had discovered 
LSD—experiencing its OBE-inducing properties—
and isolated, named, and synthesized psilocybin and 
psilocin, the psychoactive derivatives of the visionary 
Psilocybe mushroom genus (Hofmann, 1983; Luke, 
2006). The ascribing of the word psi to psychic 
phenomena during this period, however, may only be a 
coincidence. By the turn of this millennium there were 
around 200 psychedelic compounds known to science, 
a figure estimated to likely rise to 2000 compounds by 
the year 2050 at the current rate of discovery, increasing 
exponentially by a factor of ten every fifty years, starting 
with the two that were known in 1900 (Shulgin, 2004, 
2010). Despite the rapidly upwards bending curve 
of Shulgin’s formula, current quantities may even 
exceed it, as a good guestimate puts the number of 
potentially psychedelic compounds now known to man 
at about 2000 (J. Hanna, personal communication, 
August 12, 2012), given that there are something like 
1300 documented phenethylamine compounds alone 
(including substances like mescaline, MDMA, & 
2CB) known at the current time (Shulgin, Manning, 
& Daley, 2011), though they may not all be effectively 
psychoactive and have not been sufficiently tested as yet. 
However, a conservative estimate would put the number 
of known, tried, and tested psychedelics at between 250 
(J. Hanna, personal communication, August 12, 2012) 
and 300 to 400 (Shulgin, 2010). Furthermore, a more 
recent projection puts the total number of undiscovered 
drugs (not necessarily psychedelic) at 1 x1060 (Reymond 
& Awale, 2012), more than visible stars in the sky, and 
so Brown (2012b) anticipated a near limitless number of 
psychedelic compounds to arise, especially when factors 
of nanotechnology, neurostructural engineering, and 
other technological advances are additionally considered. 
Nevertheless, Brown’s projection is purely speculative, 
but it is safe to say that humans have not yet discovered 
all the psychedelic substances that will ultimately be 
available, and that there may be many more to come, 
and, with each one offering a different type of ASC, there 
remain many states yet to be discovered. Brown (2012b) 
even fancied that specific psi-inducing psychedelics may 
be intentionally engineered in the future.  
2.2 Personal Views and Experiences 
 Since the discovery of psychedelic compounds 
by the academic community and their popularization 
among the intelligentsia by the novelist Aldous 
Huxley (Smythies, 1960), there has been a steadily 
growing number of reports of paranormal experiences 
occurring with the use of these compounds. Several 
parapsychologists and psychical researchers, primarily 
from the 1950s and 1960s when psychedelic research 
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was at its peak, have endorsed the research of psi with 
psychedelics (e.g., Assailly, 1961; Broad, 1962; Hoffer, 
1961a, 1961b; Johnson, 1955; Kern, 1964; Laidlaw, 
1961; Paterson, 1961b; Price, 1948; Thouless, 1960; 
Tibbs, 1963; West, 1965). Even J. B. Rhine, the father of 
modern parapsychology, ran some informal psychedelic 
sessions in 1961 at the Rhine Research Centre in 
Durham with the then Harvard psychologists Timothy 
Leary and Richard Alpert (Black, 2001; Horn, 2009; 
Stevens, 1988), although there was apparently too much 
spontaneous laughter erupting for anyone to credibly 
test for anything (S. Abrams, personal communication, 
August 14, 2006; S. Krippner, personal communication, 
January 19, 2006). 
Notably, many other parapsychologists have 
reported personal ESP experiences with the use of LSD 
(Cavanna, 1961; Garrett, 1961b; Millay, 2001; Osmond, 
1961a; Servadio, in Alvarado, 1995), peyote/mescaline 
(Langdon-Davies, 1961; Millay, 2001; Osmond, 
1961a), psilocybin (Cavanna, 1961; Krippner, 1967; 
Millay, 2001) Amanita muscaria (Puharich, 1962), and 
ayahuasca (Severi, 1996, 1999). Krippner’s apparent 
precognitive vision of President Kennedy’s assassination 
while on psilocybin serves as a good example (Krippner, 
1967, 2006a). Though, of course, merely consuming a 
psychedelic is no guarantee that an experience of ESP 
will follow, as Price (1964) aptly demonstrated self-
experimenting with mescaline. However, other psychical 
researchers, sometimes following their own experiences, 
have noted the apparent tendency for ESP production 
with the use of psychedelics, including no less than four 
Parapsychological Association presidential addresses 
(Dean, 1967; Heywood, 1978; Hastings, 1973; Luke, 
2010b; Radin, 1989; Servadio, 1961; Stevenson, 1981). 
Furthermore, some have recommended that other 
psi researchers personally explore psychedelic states 
of consciousness to aid in their understanding of the 
concept of psi (Cavanna, 1961; Heywood, 1961). The 
most highly experienced LSD psychotherapist, Stanislav 
Grof (1980), also advised that an intimate knowledge 
of the transpersonal realms created by psychedelics is 
essential for parapsychologists. Personal accounts of 
ESP have also been reported by leading psychedelic 
mycologists (Stamets, 1996; Wasson & Wasson, 1957).
Beloff (1968) asserted that greater reporting of 
ESP on college campuses would have been evident if 
drugs induced psi particularly, to which Tart (in Beloff, 
1968) replied that many students took paranormal 
events in conjunction with psychedelics very matter-of-
factly, due to their prevalence. This point was further 
echoed by the suggestion that users of psychedelic 
drugs frequently report vivid ESP experiences but that 
they remain largely unpublished (Stafford & Golightly, 
1967). Yet, Heywood (1961) found several incidences 
of psi with LSD within the “well-evidenced” SPR 
spontaneous-case collection. However, more recently, 
Vayne (2001), echoing Tart, has suggested that among 
practiced users of psychedelics, dubbed psychonauts, 
the telepathic experience is so common that it is hardly 
remarked upon. Luke (2004c) agreed with Vayne but 
further offered that, even so, many (less well-evidenced) 
anecdotal reports could be found on contemporary 
resources on the internet. Psychedelic drug information 
sites (such as www.lycaeum.org and www.erowid.org) 
have amassed a large online archive of experiential 
psychedelic reports, among which are accounts of ESP 
experiences with substances as diverse as ketamine, Salvia 
divinorum, Psilocybe mushrooms, ayahuasca analogues, 
and 3,4-methylenedioxymethamphetamine (MDMA, 
or ecstasy) mixed with baby Hawaiian woodrose seeds, 
a natural source of lysergic acid (Anonymous, 2004a, 
2004b, 2004c, 2004d, 2004e, 2005). 
Similar reports of frequent ESP experiences with 
such substances from within the psychedelic community 
are also available elsewhere in the literature (e.g., Eisner, 
1989; Gaskin, 1990; Krippner, 2006a; Krippner & Fersh, 
1970; Lilly, 1967, 1978; McKenna, 1991; McKenna & 
McKenna, 1994; Millay, 1999, 2004a, 2004b, 2005, 
2006, 2010; Osmond, 1968; Saunders, 1993; Scully, 
2010; Stevens, 1989; Turner, 1994; Wyllie, 1999; Zelnick, 
2005). Indeed, the notion of experiencing a telepathic 
group mind, or “tribal telepathic understanding” 
(Nuttal, 1970, p. 249) through “tripping” became so 
prevalent among the psychedelic culture of the 1960s 
that prospective psychedelic users were told they might 
expect such an experience (Leary, Metzner, & Alpert, 
1964) and commonly it became known as “grokking” 
(Stevens, 1989; Wolfe, 1971). Currently, the same 
notion is still apparent among psychedelic users (e.g., 
MoDu, 2003) and the largest public-edited internet 
encyclopedia indicates that ESP-type phenomena are a 
common fourth-level experience on a five-level spectrum 
of psychedelic experience intensity (Wikipedia, 2005), 
though clearly this is not academically evidential 
but rather an indication of commonly held notions, 
among Wikipedia editors at least. Although notably, 
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PK is seldom reported in the literature, save for the odd 
exceptional report (e.g., Shulgin, 2004), and it has been 
suggested among occultists that chemical agents are only 
useful for “receptive” magic/psychic purposes, such as 
traveling clairvoyance, divination, and spirit evocation 
or invocation (e.g., Carroll, 1987; Vayne, 2001; Xeper, 
2005). The use of psychedelics for such magical purposes 
now appears to be growing in popularity among occultists 
and is seemingly far more prevalent within the literature 
than it used to be (e.g., see Louv, 2005; Kent, 2010). 
2.3 Clinical
 A review of the literature from the clinical setting 
reveals surprisingly few published psychiatric inpatient 
reports, although there are some epidemiological studies 
(see section 3.2.1) relating to psychedelics and paranormal 
experience. This may be due to any number of factors, 
such as the lack of any such spontaneous phenomena 
within the psychiatric population, or the medicalization 
within psychiatry of paranormal experiences as delusion 
or hallucination. Indeed, Mogar (1965) noted that early 
psychoanalytic and behaviorist researchers using LSD 
were prejudiced against ESP phenomena. Yet, there is one 
study, a psychiatric-interview survey with users of LSD 
(Abraham, 1983), that reports precognitive experiences as 
one of the symptoms of the LSD flashback phenomena, 
now called hallucinogen persisting perception disorder 
(American Psychiatric Association, 2000).
On the other hand, there are many accounts 
of paranormal experiences with psychoactive drugs 
from within psychedelic psychotherapy, particularly 
that involving LSD (Grof, 1975, 1980, 1990, 2001; 
Harman, 1963; Holzinger, 1964; Levine, 1968; Masters 
& Houston, 1966; Pahnke, 1968) and psychedelics in 
general (Eisner, 1995; Laidlaw, 1961; Stolaroff, 2004). 
Tart (in Levine, 1968), quoted the International 
Foundation for Advanced Study, which in the course of 
between 300 and 400 psychedelic therapy sessions has 
reported the incidence of ESP with strong evidence seven 
times, which is a considerably higher incidence of psi 
than that reported to have occurred in non-psychedelic 
psychotherapy (Tornatore, 1977a, 1977b). As one 
specific example of this line of research, the percentage 
of clients reporting telepathic communication during 
LSD-assisted therapy changed from 49% in the first 
psychotherapy session to 80% in the second session 
(Blewett & Chwelos, 1959).
The psychiatrist Stanislav Grof, generally credited 
with the most expertise in this field having conducted 
more than four thousand psychedelic therapy sessions 
over a two decade period, reported observing patients 
experiencing OBEs, ESP (particularly precognition), 
accurate remote viewing, and space-time travel on a daily 
basis (Grof, 1975, 1980, 2001). Despite acknowledging 
that there was a danger of data contamination and a 
difficulty of verification, Grof (1980) contended that 
the occurrence of ESP was relatively frequent and that 
LSD could induce states conducive to an unusually 
high incidence of ESP (Grof, 1975). Often the reports 
of telepathy could have been merely self-deception, but 
other times there was apparently objective verifiable 
communication at work (Grof, 1980). Grof further 
found the common occurrence of OBEs, both within 
and independent of this physical plane, often with 
traveling clairvoyance and clairaudience. There were 
also occasional NDE experiences reported (Grof, 1994). 
Most frequent was the occurrence of extraordinary 
coincidences or synchronicities, yet only among those 
clients who experienced transpersonal breakthroughs 
within the psychedelic session (Grof, 1980). Finally, Grof 
(1990) also reported two events, rare in the literature, 
of clients under LSD who experienced visions of the 
dead that provided apparently unknown, but verifiable 
information. One such event occurred to the wife of the 
late psychedelic-psychical researcher Walter Pahnke. 
During an LSD session, Mrs. Pahnke had a vision of 
her dead husband who requested her to return a book 
concealed in her attic. Although she claimed to have 
had no prior knowledge of the book, she managed to 
locate and return it. Of course, it is possible that the 
knowledge of the book already lay in her subconscious 
(Stokes, 1997). 
One of the most astonishing reports of psi 
occurring within the clinical setting came from 
the psychiatrist Paul (1966), who reported taking 
the mushroom Amanita pantherina. This was her 
only psychedelic experience and was part of an ESP 
experiment being conducted by Puharich (see Puharich, 
1959, 1962). Paul had an incredibly intense trip, 
complete with apocalyptic visions followed by salvation 
through overwhelming love, and was unable to complete 
the experiment. However, on return to her practice, 
two of her clients reported extraordinary events at the 
time Paul had been tripping. One patient had amnesia 
for the same three hours on Friday evening following 
the consumption of his first-ever (non-psychedelic) 
mushroom meal, and upon remembering his experience, 
International Journal of Transpersonal Studies 116 Luke
recalled that he had experienced the same apocalyptic 
fears as Paul had experienced. The other patient could 
not remember what she had done that evening but on 
investigation discovered that she had gone to the house 
of a secret lover and waited outside, love-struck, for two 
hours, but was prevented from taking any irrational 
action by her friend, who later informed her of the event. 
Both patients had a strong bond with the therapist 
and had expressed an interest in ESP. Paul interpreted 
the event as a case of spontaneous telepathic tripping, 
complete with amnesia on the part of the receivers, 
perhaps demonstrating a certain unpredictability in the 
experimental induction of psi with psychoactive drugs. 
2.4 Evaluation of Field Reports
 In summary, there is a wealth of reports of 
the spontaneous occurrence of ostensibly paranormal 
phenomena with the use of psychedelic substances. 
Yet this does not mean that these experiences are 
necessarily genuine paranormal events: Aside from 
the usual arguments for and against spontaneous 
phenomena as evidence for the paranormal (e.g., see 
Pekala & Cardeña, 2000; Stokes, 1997), the fact that 
respondents had consumed a visionary substance may be 
reason to question their perception and interpretation of 
the experiences, at least for those cases which are not 
substantiated by evidence or independent observers. 
Nunn, Rizza, and Peters (2001) have found that cannabis 
use is related to delusional ideation, although it is not 
directly related to delusional conviction; however, the 
relationship between psychedelic use and the propensity 
for false memory and poor probability judgments has 
not been established (Kapur & Seeman, 2002; Wilson 
& French, 2006). Furthermore, Shanon (2003) pointed 
out that the usual definitions of hallucination in the 
psychological literature fail to adequately encompass 
the diverse and complex nature of experiences that 
occur with psychedelics, and nor can assumptions be 
made about the ontology of such psychedelic-induced 
visions. Indeed, many people who have had paranormal 
psychedelic experiences reported how real the experience 
seemed, often being felt as more real than the ordinary 
waking experience (e.g., Hofmann, in Grof 2004; 
Shanon, 2003; Strassman, 2001). It has also been 
reported that psychedelic-induced mystical experiences 
feel no less real than previous spontaneous mystical 
experiences (Doblin, 1991; Exman, 1961; Greeley, 1974; 
Griffiths, Richards, McCann, & Jesse, 2006; Pahnke, 
1966; Pahnke & Richards, 1966; Roberts, 2001; Smith, 
2000; Smith & Tart, 1998; Watts, 1968), the same being 
true for NDEs (Jansen, 2001). 
In defense of drug-induced altered states, 
Devereux (1997) has suggested that, “it is a culturally 
engineered cliché to dismiss such states as being 
somehow delusional” (p. 243). Furthermore, Smythies 
(1960, 1983) has taken issue with the concept of dulled 
and hallucinatory psychedelic states and insisted that 
these hallucinations are more than just images from a 
poisoned brain.  Additionally, LeShan (1968) has mocked 
the assumption that ordinary reality is somehow more 
real than the psychedelically induced ASC, whereas Tart 
(1977) questioned how natural is the ordinary state of 
consciousness, built through a lifetime of socialization. 
Tart (1972, 1998, 2000, 2001) further questioned the 
idea that rationality only occurs in the ordinary state, 
and proposed the establishment of state-specific sciences 
(for further discussion see Walsh, 2003)
No matter what their epistemological status, 
however, these experiences do offer a phenomenological 
spectrum of evidence around which to orient further 
research. Furthermore, the similarity in reports 
between those occurring spontaneously in exploratory, 
therapeutic, and accidental contexts, and those induced 
intentionally in the traditional ritual context, gives 
credence to the shamanic use of these substances for 
supposedly paranormal purposes. By contrast, other 
traditional psychoactive substances, such as alcohol, 
coffee, and cocaine are not contemporaneously reported 
to induce spontaneous paranormal phenomena, and 
neither are there folk beliefs that suggest they do. 
Nevertheless, Rogo (1975) wondered whether the 
occurrence of psychedelic-induced ESP experiences 
exceeded that of normal ESP experiences, a question 
that may be partially answered by survey research. 
3. Surveys
  When reviewing the survey research one 
immediately notices two trends. First, virtually all of the 
surveys reported here were published since the 1970s, 
after the period when most psychedelic research was 
conducted and the unlicensed use of these drugs mostly 
became illegal in Europe and North America. Secondly, 
most of the following surveys have primarily focused 
on paranormal experiences or belief and have only 
recorded drug use information as one of many possible 
co-variables, often omitting to distinguish among the 
different substances. Only a few studies (DeGracia, 
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1995; Kjellgren & Norlander, 2000; Tart, 1993; White, 
1997) have approached users of psychoactive substances 
as the target sample. 
3.1 Surveys of Belief in the Paranormal 
Investigating belief in the paranormal with the 
Mental Experience Inventory (MEI), Kumar, Pekala, 
and Cummings (1992) additionally utilized a sensation 
seeking scale that included a yes/no question about 
recreational drug use. Of an opportunity sample of 
574 psychology students, drug users reported greater 
paranormal and psi-related beliefs; however, results were 
reported in terms of the larger sensation-seeking measure 
as significant main effects. In a more direct assessment of 
the relationship, Gallagher, Kumar, and Pekala (1994) 
transformed the MEI into the Anomalous Experiences 
Inventory (AEI; Kumar, Pekala, & Gallagher, 1994), 
adding a Drug-Use subscale to complement the other 
four subscales relating to Anomalous/Paranormal Belief, 
Experience, Abilities, and Fear. The AEI was successfully 
validated against other paranormal experience and belief 
scales using an opportunity sample of 400 psychology 
students. The AEI Drug-Use subscale correlated 
positively, although only very weakly, with the AEI 
Anomalous/Paranormal Beliefs subscale (r = .16, p < .01) 
and with Tobacyk’s (1988) paranormal belief subscales: 
Belief in Psi (r = .10, p < .05), Belief in Witchcraft (r = .12, 
p < .05), Belief in Superstition (r = .11, p < .05), Belief in 
Spiritualism (r = .17, p < .01), Belief in Extraordinary Life 
Forms (r = .13, p < .01), but not Belief in Precognition. 
Drug use correlated negatively with Traditional Religious 
Beliefs (r = -.14, p < .01).
In addition, some items in the AEI Drug-
Use subscale correlated with Tobacyk’s (1988) Revised 
Paranormal Belief Scale, although only very weakly. 
Overall, paranormal belief correlated negatively with 
heroin use (r = -.12, p < .05) but positively with the use of 
LSD (r = .11, p < .05) and mind-altering substances (r = 
.15, p < .01). There were no significant correlations found 
for marijuana, cocaine, or alcohol. The same correlations 
were found between the AEI Anomalous/Paranormal 
Belief subscale and some AEI Drug-Use subscale items 
(mind altering substances, r = .18, p < .001; LSD, r = 
.15, p < .01), but also including marijuana (r = .16, p < 
.01), but not heroin. Additionally, for all categories of 
drugs except heroin there was a small significant negative 
correlation with the fear of psi (from r = -.12 to -.24), 
whereas alcohol use correlated positively with fear of 
psi (r = .13, p < .05). The lack of a consistent significant 
correlation between paranormal belief and marijuana 
use runs counter to Tart’s (1993) finding that 76% of 
marijuana users believe in ESP. This difference may 
be due to cohort differences, such as culture and their 
reasons for using marijuana, or that Tart’s marijuana 
sample were mostly also experienced with LSD (72%, 
with 36% classified as heavy psychedelic users; Tart, 
1971), a drug that Gallagher et al. (1994) did find to 
be related to paranormal belief. Furthermore, it should 
be noted that the items of the AEI Drug-Use subscale 
only register nominal yes/no responses, whereas more 
sensitive ordinal drug-use measures would have been 
expected to demonstrate stronger correlations, if the 
relationships were linear. Nevertheless, correlations from 
this study reported here are uncorrected and should 
be accepted with some caution because of the use of 
multiple inferential tests. 
Pekala, Kumar, and Marcano (1995a, 1995b) 
sought to find a relationship between the subscales 
of the AEI and measures of hypnotic susceptibility 
and dissociation on a similar opportunity sample of 
413 psychology students. Supporting the Gallagher 
et al. (1994) study findings, the Drug-Use subscale 
correlated positively, and somewhat more strongly, with 
Anomalous/Paranormal Beliefs (r = .25, p < .001) as well 
as negatively with Fear of the Anomalous/Paranormal 
(r = -.14, p < .01), although no breakdown of the results 
for the Drug-Use subscale was given for the different 
substances. In addition, overall drug use was found not 
to correlate with dissociation or hypnotic susceptibility, 
although marijuana was a special case (see Pekala et al., 
1995b).
A later opportunity sample of 107 students 
(Houran & Williams, 1998) were surveyed using the 
AEI to explore the equivocal relationship between belief 
in the paranormal and tolerance of ambiguity. Further 
support was demonstrated for the small but significant 
relationships between drug use and anomalous/para-
normal belief (r = .22, p < .05) and fear of the anomalous/
paranormal (r = -.18, p < .05). Tolerance of ambiguity 
was found to correlate minimally with both paranormal 
belief and drug use (r = .23, p < .05), and more so with 
psychedelic drugs (LSD, marijuana), rather than cocaine, 
alcohol, or heroin. 
Simmonds and Roe (2000) used the AEI 
in relation to schizotypy, temporal lobe lability, and 
personality correlates with an opportunity sample of 
145 psychology students. Similarly to previous surveys, 
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there was a small significant correlation between drug 
use and anomalous/paranormal belief (r = .20, p < .05). 
Drug use was also found to relate to complex partial 
epileptic signs (CPES) as measured by a subscale of the 
Personal Philosophy Inventory developed by Persinger 
and Makarec (1987), which they had predicted would 
be the case. However, it is apparent that several items of 
the CPES are consistent with experiences often reported 
in other ASCs, drug-induced or otherwise, so such a 
correlation might be expected anyway. Furthermore, 
neither of these correlations remained significant when 
the alpha level was recalculated using a Bonferroni 
correction for multiple tests, although the relationship 
between drug use and belief remains consistent with 
these other surveys, so this correlation is probably 
genuine, albeit small. 
A later survey (Thalbourne, 2001) using the 
AEI sought to replicate the relationship found by 
Gallagher et al. (1994) between drug use and belief 
in the paranormal, and in addition investigated this 
relationship with respect to transliminality and to 
kundalini experiences. Transliminality was measured 
using the 29-item Transliminality Scale (Thalbourne, 
1998), before it was rasch-scaled for age and gender bias. 
Using an opportunity sample of 125 psychology students, 
Thalbourne found a small significant positive correlation 
between the AEI subscales: Drug-Use and Anomalous/
Paranormal Belief (r = .24, p < .01), supporting previous 
findings. There was a suggestive but non-significant 
negative correlation between drug use and fear of the 
anomalous/paranormal. There was also a significant 
positive correlation between drug use and transliminality 
(r = .29, p = .001) and the New Age Philosophy (NAP) 
subscale of the Tobacyk’s (1988) Revised Paranormal 
Belief Scale (r = .23, p < .01). There was, however, no 
significant correlation with Tobacyk’s Traditional 
Paranormal Beliefs (TPB) subscale, and reanalysis of 
Thalbourne’s data by Houran and Lange (2001) found 
the difference in reports of drug use in relation to NAP 
and TPB to be significant (p < .001, uncorrected for 
multiple analyses), reinforcing their argument for two 
distinct paranormal belief groups. Furthermore, drug-
use did not correlate with Thalbourne and Delin’s 
(1993; non-rasch scaled) Australian Sheep-Goat Scale, 
a different paranormal belief scale (Thalbourne, 2001). 
These findings partially support Gallagher et 
al.’s (1994) small positive correlation of drug use with 
the Tobacyk Belief in Psi subscale, yet to what extent is 
not discernable because Thalbourne’s (2001) results were 
reported in terms of just two collapsed subscales rather 
than the full seven. The same is also true of correlations 
between Anomalous/Paranormal Belief and the Drug-
Use subscale, although of note, very few respondents used 
heroin (n = 3) and cocaine (n = 6) compared to LSD (n 
= 26) or marijuana (n = 61), indicating that correlations 
with those reporting drug use (n = 57, obviously some 
of the respondents did not consider marijuana to belong 
to this category) were largely in terms of psychedelics 
rather than other drugs. 
A post hoc analysis of the relationship between 
transliminality and drug use revealed there were small, 
but significant, positive correlations (ranging from 
r = .20 to .27) between transliminality and all of the 
AEI drug-use categories (mind-altering substances, 
marijuana, LSD, cocaine, and heroin) except for alcohol. 
Thalbourne (2001) suggested that this relationship may 
be due to the need to use drugs to escape the unpleasant 
aspects of the transliminal state, or that drug use may be 
a means of promoting the psychic phenomena of which 
high transliminal scorers may have become deprived. 
Both of these hypotheses might prove to be somewhat 
correct, but only for differing substances. It is highly 
unlikely that psychedelic drugs are used to escape the 
transliminal state because these substances are actually 
more likely to cause the opposite effect, although some 
non-psychedelic drugs, such as opiates/opioids might 
help to escape transliminality. Indeed, Vayne (2001) 
has suggested psychedelics are expressly used to access 
liminal states. Alternatively, Thalbourne has speculated 
that an “openness to experience” trait underlies the 
relationship between drug use, transliminality, and 
paranormal experience. 
In a follow-up survey (Thalbourne & Houran, 
2005), an opportunity sample of 200 psychology students 
completed the Revised Transliminality Scale (Lange, 
Thalbourne, Houran, & Storm, 2000), and an extended 
version of the AEI Drug-Use subscale, which included 
two extra items, one relating to ecstasy (MDMA) and 
one relating to speed (amphetamines). As previously, 
though somewhat less so, drug use was found to correlate 
marginally, although significantly, with transliminality 
(r = .21, p < .005, one-tailed). Furthermore, scores on 
the Oxford Happiness Questionnaire demonstrated 
that transliminality was not related to happiness and 
that the majority of high transliminals were happy, 
offering support to McCreery and Claridge’s (1995) 
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notion of the pathology-free “happy schizotype” prone 
to paranormal experiences. However, unhappy high-
scoring transliminals reported significantly more drug 
use than happy high-scoring transliminals (t = 1.98, n = 
77, p < .05), somewhat supporting Thalbourne’s (2001) 
speculation that transliminality, akin to psychosis, can 
be a unhappy state that such people attempt to escape 
from with drugs. Unfortunately, Thalbourne and 
Houran’s findings sweep several different types of drugs 
—including psychedelics, narcotics, stimulants, and 
alcohol—together under one umbrella, revealing very 
little about which of these very different drugs relate to 
each particular syndrome. For instance, given the system 
of scoring in this study, it is easily possible that the use of 
just one drug, such as alcohol, entirely accounts for the 
differences in substance use between happy and unhappy 
transliminals, and further research begs more specific 
analyses. 
Here Metzner (2005) pointed out that, aside 
from merely varying in how they activate or relax one’s 
nervous system, psychoactive drugs may also be classified 
along a hedonic continuum of pain and pleasure, 
reflecting Thalbourne and Houran’s (2005) simplified 
notions about drugs and the quest for happiness. 
However, taking a transpersonal approach, Metzner 
further indicated that drugs may also be considered 
along a third dimension of consciousness expansion 
and contraction, such that psychedelics are essentially 
conscious expanding, whereas opiates, alcohol, cocaine, 
and amphetamines, being focally restrictive and 
addictive, are consciousness contracting. Thus, a range of 
drugs can be used when seeking stimulation, sedation, or 
happiness, but only specific drugs, psychedelics, will lead 
to consciousness expanding experiences, and perhaps 
even ostensibly paranormal ones too. Arguments may 
prevail over precise definitions and classifications here, 
but the point remains that psychological research would 
most likely benefit from a recognition of the experiential 
differences between drugs rather than just a recognition 
of their legal status and a crude categorization of them 
based only on that (Friedman, 2006).   
3.2 Surveys of Paranormal Experiences.
3.2.1 Psychiatric epidemiological samples. 
Recently, a wealth of epidemiological psychiatric research 
has surveyed reports of cannabis use and schizotypal 
symptoms, finding fairly consistent correlations between 
them (for a review, see Castle & Murray, 2004). 
Items relating to telepathy and other kinds of thought 
broadcasting have been often included, and it deserves 
mentioning that the subscales in which theses items 
appear tend to correlate with cannabis use (e.g., Johns 
et al., 2005). However, although relevant, this research 
is largely indirect to the present review as incidence 
rates for specific types of paranormal-like experiences 
are rarely reported, but rather form part of more general 
subscales. 
More specifically, in a quasi-experimental 
design with 196 university students, Nunn, Rizza, and 
Peters (2001) found that cannabis use, but not alcohol 
use, was positively related to unusual experiences (such 
as the possession of special, almost magical powers), but 
use of either drug was unrelated to depression or anxiety. 
Furthermore, cannabis use was related to delusional 
ideation but not distress, further supporting the notion 
of the happy schizotype, although cannabis and alcohol 
use combined was related to delusional conviction. Nunn 
et al. suggested that schizotypal traits may predispose 
subjects to cannabis use or that cannabis use may result 
in high schizotypy scores. Although some prospective 
studies have been conducted in this area, there are often 
so many possible confounding factors involved in such 
research that directions and sources of causality remain 
entirely speculative (see Castle & Murray, 2004).
3.2.2 Clinical populations. Finding numerous 
paranormal experiences reported in a DXM-users 
survey (see section 3.2.4 to follow), White (1997) 
sought to explain the survey results in terms of temporal 
lobe dysfunction (TLD). Tentative indirect support 
comes from a survey of a convenience sample of 100 
neuropsychiatric patients where a positive recreational 
drug-use response was used, among other measures, as 
a predictor of TLD, with TLD correlating well with 
reports of subjective paranormal experience (Palmer 
& Neppe, 2003). However, the recreational drug-
use measure utilized a blanket definition that lumped 
together the use of a variety of different psychoactive 
drugs and moreover treated drug use alongside brain 
injury as causative factors in TLD, although there is 
no clear reasoning given for doing this. In this study, 
recreational drug use was taken to be either of the 
following: prolific marijuana use; the three times use of 
hallucinogens, LSD, mescaline, or PCP; or six months’ 
use of heroin or amphetamine. However, it was reported 
in a later paper that, when gender was controlled, there 
were no relationships between subjective paranormal 
experiences and any of the categories of drug use or 
International Journal of Transpersonal Studies 120 Luke
brain injury with this sample (Palmer & Neppe, 2004), 
although results may be due to underpowered statistics 
with only six respondents in this group. 
3.2.3 General and student samples. Several 
major surveys of psychic experiences have included 
questions regarding the use of psychoactive drugs. The 
first series of surveys of this nature utilized a psychic 
experiences questionnaire created by Palmer (1979) 
for use in a randomly distributed postal survey. The 
questionnaire was completed by 354 townspeople (T) 
and 268 students (S), treated as different samples, with 
response rates of 51% and 89% respectively. Those who 
acknowledged the use of mind-expanding drugs also 
responded positively to being an ESP agent, having a 
recurrent spontaneous PK experience (T only, p < .01, 
although Palmer urged caution with these two results 
because of low responses), haunting experience (T only, 
p < .05), aura vision (S, p < .05), and OBEs (S, p < .01). 
Despite reported drug-use differences between samples, 
equal proportions from each group (T: 29%; S: 28%) 
reported psi experiences actually occurring during use. 
Kohr (1980) criticized the analysis for not reporting the 
chi-squared statistic and for using an underpowered test. 
Kohr (1980) surveyed a special sample of self-
selecting respondents (n = 406) from the Association for 
Research and Enlightenment, an organization whose 
membership represented those intrigued by the legacy of 
the renowned psychic and Christian mystic Edgar Cayce. 
Using Palmer’s (1979) questionnaire, Kohr failed to find 
any association between subjective paranormal phenomena 
and the use of mind-expanding drugs, although figures 
for drug use were not actually reported. It is suspected 
that the drug use statistics were not reported in this study 
because its incidence was quite low. The Kohr sample 
was both older (61% over 40 years) and markedly more 
religious (40% = very religious) than the Palmer samples 
(over 40 years, T = 51%, S = 0%; very religious, T = 8%, S = 
9%), and, as stated earlier, Gallagher et al. (1994) found 
traditional religious beliefs to correlate negatively with 
drug use. Roney-Dougal (1984) surveyed a different special 
sample, attendees at an occult conference, about their psi 
experiences. Of the 33 respondents, 30 (91%) reported psi 
experiences, of which 12 (40%) reported the use of mind-
expanding drugs. This indicates both the slightly higher 
reported use of psychedelics (36% of the sample) and 
the greater reporting of paranormal experiences among 
occultists compared to other populations, though this 
observation may not be reliable.
Another survey (Usha & Pasricha, 1989a, 
1989b) modified Palmer’s (1979) questionnaire, 
particularly the demographic questions, to suit the 
needs of an Indian student population (n = 328; 
response rate 79% using opportunity sampling). Use of 
mind-expanding drugs was reported by 11%, who were 
also significantly more likely to be Hindu (p < .05) or 
male (p < .01), probably largely due to the sacred use of 
marijuana among many Indian men, mostly Hindus. Of 
those reporting drug use, 18% reported psi experiences 
during the drug experience, somewhat less than Palmer’s 
28-29%. Similar to Palmer’s work, the use of mind-
expanding drugs was positively associated (chi-squared) 
with OBEs (p < .01), and additionally with waking ESP 
(p < .05), apparitions (p < .01), and déjà vu experiences 
(p < .01). Except for apparitions, these three experiences 
tended to correlate significantly with other psi-relevant 
experiences such as lucid dreaming, meditation, and 
mystical experiences. None of the studies using Palmer’s 
46-item questionnaire (Palmer, 1979; Kohr, 1980; 
Usha, & Pasricha, 1989a, 1989b) made any corrections 
for multiple inferential analyses, so results should be 
accepted with some caution.
Returning to the surveys of paranormal belief 
among students reviewed in the previous section (3.1), 
these studies also investigated anomalous/paranormal 
experiences, and Kumar et al. (1992) found drug users 
reported significantly more of these. The later series of 
five surveys (Gallagher et al., 1994; Houran & Williams, 
1998; Pekala et al., 1995a, 1995b; Simmonds & Roe, 
2000; Thalbourne, 2001), utilizing the Anomalous 
Experiences Inventory (Gallagher et al., 1994), each 
reported a significant positive relationship between 
the Anomalous/Paranormal Experience and Drug-Use 
subscales. Correlations ranged from r = .13 (Gallagher 
et al., 1994) to r = .29 (Thalbourne, 2001), and Pekala 
et al. (1995a) additionally found that drug use was 
positively correlated with a Shamanic or Encounter-
like Experiences subscale (r = .23; p < .001), which 
included items relating to OBE and contact with spirits. 
Furthermore, Pekala et al. (1995b) reported correlations 
between the use of certain substances and subjective 
psychic experiences occurring under the influence 
of drugs, although results were only given for high 
hypnotically susceptible participants (n = 56; for the 
AEI Drug-Use subscale r = .57, p < .01; mind-altering 
substances r = .34, p < .01; marijuana use r = .30, p < 
.05) and high dissociative participants (n = 59) (Drug-
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Use subscale r = .58, p < .01; mind-altering substances r = 
.30, p < .05; LSD r = .41, p < .01; cocaine r = .34, p < .01).
Thalbourne (2001) also found a relationship 
between drug use and kundalini experiences (r = .28, 
p < .01) measured using the 32-item Kundalini Scale 
(Thalbourne & Fox, 1999). It was suggested by Thalbourne 
that the relationship between paranormal experience, drug 
use, and the kundalini experience either indicates that 
certain drugs may trigger a kundalini experience or that 
that the use of drugs may alleviate it. Alternatively, it was 
proposed that the relationship between these factors may 
also indicate a need for non-standard sensations, or that 
the physiological aspects of the kundalini experience were 
being misinterpreted as paranormal. This final supposition 
is not consistent with long established tantric teachings 
that warn of genuine psychic kundalini experiences 
called “siddhis” (e.g., Satyananda, 1996). Furthermore, 
as an alternative to Thalbourne’s interpretations, the 
results may simply be due to an overlap of subjective 
psychic experiences common to both the kundalini and 
the drug experience, as suggested by Naranjo (1987) and 
demonstrated by DeGracia (1995) in the following section 
(3.2.4). Perhaps the activation of the pineal gland and 
its chemistry, as supposed by Roney-Dougal (e.g., 2001) 
and Strassman (2001), underlies both factors, resulting in 
subjective paranormal experiences. Indeed, Roney-Dougal 
(1989, 1991) noted that the pineal gland is considered 
by some yogis to be primary in the control of kundalini 
psi experiences, and there is other putative evidence (see 
section 1.1) that suggests such a link.
3.2.4 Psychedelic-users samples. DeGracia 
(1995) conducted a self-selecting internet survey with 
61 experienced psychedelic users about their experiences 
of kundalini-like phenomena. Of those responding, 
58% had used psychedelics more than 20 times, most 
frequently LSD (95%), and psilocybin (82%). The 
respondents revealed a large overlap between reported 
psychedelic experiences and those experiences commonly 
arising in spontaneous kundalini awakenings. Of 
particular interest, psychedelic drug users frequently 
reported an enhanced sense of empathy (75%), OBEs 
(40%), intuition, psychic powers, and the recall of past 
lives (no statistics given). That the use of psychedelics is 
related to both paranormal and kundalini experiences is 
further supported by the survey findings of Thalbourne 
(2001), as discussed in section 3.2.3
One of the first surveys (Ditman et al., 1969) 
to explore paranormal experiences with psychedelics 
randomly gave 99 alcoholics receiving treatment one of 
the following three drugs: LSD (the only psychedelic of 
the three), methylphenidate (a dopaminergic stimulant, 
also known as Ritalin), or chlordiazepoxide (the first 
benzodiazepine, a sedative/hypnotic). Those taking 
LSD reported significantly more of the paranormal-type 
phenomena, having more experiences of transcending 
time and of having an OBE supporting findings with 
the AEI that dopaminergic stimulants (i.e., cocaine) are 
not conducive to paranormal beliefs. 
A survey (Tart, 1970, 1971, 1993) conducted 
in California in 1970 with 150 experienced users of 
marijuana recruited by discrete snowball sampling found 
even higher reports of paranormal experiences than the 
student and general samples discussed above (section 
3.2.3). The marijuana-user sample consisted of 76% 
students, and 72% of the sample had tried LSD, although 
only 7% had tried hard narcotics (e.g., presumably 
heroin). With regard to experiences under the influence 
of marijuana, 69% reported telepathy (rising to 83% 
in a later sample), 32% reported precognition, 13% PK 
(defined as magical operations that cause an effect), and 
50% reported seeing auras, with heavier users reporting 
significantly higher frequencies of these experiences 
in each category (Tart, 1971). OBEs were reported by 
44%, with 53% of this group reporting a least one OBE 
under the influence (Tart, 1971). In comparison, a later 
survey (Luke & Kittenis, 2005) found that somewhat 
smaller percentages of experienced cannabis users (i.e., 
those using it often or more frequently, n = 60) than in 
Tart’s study reported the occurrence of telepathy (20%), 
precognition (12%), psychokinesis (12%), and auras 
(22%) while under the influence. Yet, the percentage 
reporting OBEs either with or without cannabis (62%) 
was larger than in Tart’s study (44%). The use of 
Californian students at the epicentre of the psychedelic 
scene at that time may at least partially account for Tart’s 
heightened findings, perhaps because these respondents 
were more psychedelically active and responsive, and 
consuming higher quantities and grades of cannabis 
than in the 2005 survey. 
A survey, similar to DeGracia’s (1995) 
investigation of transpersonal drug experiences, was 
conducted in Sweden with an anonymous snowball 
sample of 16 experienced psychedelic drug users 
(Kjellgren & Norlander, 2000). Of those returning 
questionnaires (94%), 37% had used psychedelics more 
than 20 times, mostly LSD (75%) and psilocybin (75%). 
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Respondents indicated the occurrence of OBEs (53%), 
telepathy (60%), the loss of the sense of a discrete self 
(47%), psycho-geographical traveling (62%), contact 
with entities (20%), time-travel (40%), animal shape-
shifting (53%), and visions of mythological beings (33%), 
all under the influence of psychedelics. All respondents 
reported having some psi experiences, with heavier users 
and, similarly to Usha and Pasricha (1989a, 1989b), those 
practicing mind-expanding, spiritual, or ritual techniques 
or preparation reported more of these experiences than 
infrequent users. However, significant differences in the 
quantity of experiences between low and high users only 
occurred for the experiences of telepathy (U = 12, p < 
.05, two tailed) and gaining knowledge of oneself, and 
for a combined index of all paranormal experiences (U 
= 7, p < .05), though uncorrected for multiple analyses. 
This partially supports the hypothesis that subjective 
paranormal experiences occur more frequently during 
the use of psychedelics, although alternative explanations 
are possible. Furthermore, 31% of the sample reported 
that their views on life after death have been influenced 
by their use of psychedelics, and 44% had become less 
afraid of death through their experiences, although 12% 
had become more afraid. 
In further support of the notion that greater 
psychedelic use is associated with more paranormal 
experiences, a limited survey of 67 psilocybin-containing 
mushroom users found that only 9% of those taking low 
doses (less than 5 dried grams of Psilocybe cubensis) had 
experiences of telepathy, whereas 28% of those taking 
higher doses—what McKenna (1991) called a heroic 
dose—had telepathic experiences (Hurst, 1994). 
Of particular interest to the present review 
are the results of an incidental internet survey (White, 
1997) of subjective paranormal experiences with the use 
of the dextromethorphan (DXM). Commonly used in 
cough remedies DXM is a synthetic drug that results 
in similar subjective experiences to other dissociatives, 
such as ketamine and PCP. White was concerned about 
the use of DXM and had a “frequently asked questions” 
report regarding DXM posted on an internet-based 
psychoactive drug information site (www.erowid.org). 
The published survey, unfortunately without statistics or 
demographics, was the product of reports sent to White 
from people who had used DXM, often unwittingly as a 
simple cough remedy, and had experienced a number of 
subjective paranormal experiences. White was surprised 
at the reports and was originally very reluctant to 
take them seriously, until he received so many that he 
collated, categorized, and published them. 
Many of the experiences reported by White 
(1997) are consistent with experiences common to 
ketamine use (Jansen, 2001; Corazza, 2002) and include 
the following: visions of energy ribbons; a disturbing 
sense of infinity; a sense of presence of a profoundly 
powerful, loving, and intelligent being (as is also quoted 
with DMT use, a very different substance—Strassman, 
2001); déjà vu; jamais vu; a loss of sense of causality; 
memory loops; a sense of presence; OBEs (most often 
to a different dimension but also on the corporal plane 
outside of one’s body); NDEs; contact with entities, 
spiritual beings, and other free-floating consciousnesses 
(also reported by Carpenter, 2006; Xeper, 2005); 
occasional ESP, including clairvoyance; and the intuitive 
understanding of complex ideas such as a math student 
understanding Gödel’s Incompleteness Theorem for the 
first time. Most of these experiences have since elsewhere 
been reported in an online user journal, The DXM Zine 
(Gelfer, 2007). It is noted there were no reports of PK, 
although some felt that they could slightly influence 
the laws of probability. These reported experiences are 
independently consistent with a psychiatric inpatient 
report of an apparently accidental overdosing with 
a cough remedy containing DXM (Price & Lebel, 
2000). Reported symptoms included the experience of 
observing oneself from outside of one’s body (OBE), 
becoming “just thoughts,” 360° vision, vision within 
people, and “delusions” of telepathy, all of which ceased 
when the DXM wore off. 
Taking a more taxonomic approach than earlier 
research, Luke and Kittenis (2005) sought to determine 
which of a range of psychedelics are related to which 
paranormal experiences in particular. The online survey 
pooled responses from 139 self-selecting respondents 
recruited via both parapsychology and psychedelic 
interest groups. The percentage of respondents who had 
tried an illicit drug even once (n = 110) and who reported 
a psi experience while under the influence (47%) was 
somewhat higher than the 28-29% and 18% found 
previously with general and student samples (Palmer, 
1979; Usha & Pasricha, 1989a, 1989b), as might be 
expected from this non-ordinary sample. 
The study also corroborated many of the 
observations made in previous research. For example, 
supporting Strassman (2001), DMT was widespread in 
inducing entity contact experiences and OBEs, although 
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primarily to other dimensions, and like 5-MEO-DMT, 
DMT commonly gave the experience of dissolving 
into a universal energy. The hypothesis that DMT is 
fundamental to the NDE (Strassman, 2001) was partially 
borne out by the relatively widespread reporting of the, 
albeit generalized, death-like experiences (dying, rebirth, 
or memory of a past life) although such experiences 
seemed to be relatively more widespread with 5-MEO-
DMT, as observed elsewhere (Luke, 2005; Roney-
Dougal, 2001; Shulgin & Shulgin, 1997). 
Reports of “sensing an intelligence or spirit being 
in an ingested plant or substance” were found to be most 
widespread where respondents were under the influence 
of plant-based substances: psilocybin-containing 
mushrooms, ayahuasca, mescaline-containing cacti, and 
Amanita muscaria, but especially with Salvia divinorum, 
as has been documented elsewhere (Aardvark, 2002; 
Addy, 2010; Arthur, 2010; Doyle, 2012; Horner, 
2012; Miller, 1994; Vayne, 2001). For a discussion of 
interspecies encounters on psychedelics see Krippner 
and Luke (2009). Such plant-spirit experiences also 
occurred with the use of the cannabis plant, although 
the most widespread experiences with this drug were 
clairvoyance and OBEs on this plane and, primarily, 
telepathy, making this substance a prime candidate for 
ESP research, as has already been advocated by Tart 
(1993) for a number of reasons. The dissociative DXM 
is also a potential candidate for further ESP research, 
particularly collective ESP experiences, supporting 
earlier reports of psi occurring with its use (Gelfer, 
2007; Price & Lebel, 2000; White, 1997). There were 
also relatively widespread reports of telepathy with LSD 
and particularly with MDMA, a drug, categorized as 
an empathogen, that is characterized by its capacity to 
induce empathic experiences and that has elsewhere been 
reported to induce telepathic experiences (Brown, 2012a; 
Eisner, 1989; Saunders, 1993). Psilocybe genus mushrooms 
too demonstrated some relatively widespread capacity 
to accompany psi experiences of all kinds, particularly 
clairvoyance, but even PK to some extent. However, 
possibly because of the more infrequent experience of 
PK, there did not seem to be any one substance that 
was related to it, with the possible exception of Psilocybe 
mushrooms, mescaline, and LSD, although none of 
these convincingly.
In keeping with the previous findings of 
correlations, ranging from r = .13 to .29, between the 
occurrence of paranormal experiences (including 
mystical experiences) and the use of all drugs (excluding 
prescription drugs) as measured with the AEI (see section 
3.2.3), the Luke and Kittenis (2005) study also found 
a positive correlation of r = .46, p < .001. The greater 
correlation in this study most likely was due to the use 
of different sample types, and variations in the questions 
used. In addition, an overall correlation was calculated 
between the frequency of paranormal experiences 
and the frequency of drug use (excluding alcohol and 
prescription drugs) that gave a small positive value of 
r = .31, p < .001, supporting Kjellgren and Norlander’s 
(2000) and Tart’s (1971) finding that greater psychedelic 
use is related to more paranormal experiences.
3.3 Surveys and Out-of-Body Experiences (OBEs)
The connection between psychoactive substances 
and OBEs has received special attention. An inspection 
of the SPR files led Whiteman (1956) to summarize 
that approximately a third of “separation” (OBE) cases 
were initiated by physical conditions, including drugs, 
although which drugs are not specified. Drug type is 
clearly of relevance, however, as a study experimentally 
comparing LSD with Ritalin and benzodiazepine 
experiences also found that LSD induced a significantly 
greater degree of OBEs (Ditman et al., 1969). Since the 
1950s and 1960s several OBE surveys have incorporated 
questions relating to drug use. Combining two 
convenience samples of students (n = 192), Blackmore 
(1982) reported that of the 35 (18%) claiming to 
have had at least one OBE, 13 (37%) occurred when 
taking drugs, most often LSD or marijuana. A later 
questionnaire survey with students (convenience sample, 
n = 96) found 31% claimed to have had an OBE, and 
they were significantly more likely than those who did 
not claim to have had an OBE to have taken drugs such 
as cannabis, LSD, or opium derivatives (Blackmore & 
Harris, 1983). 
In a similar survey of students from an 
opportunity sample (n = 200), Myers, Austrin, Grisso, 
and Nickeson (1983) utilized the OBE question from 
Palmer’s (1979) questionnaire and found a significant, 
but small, correlation between reported OBEs and the 
use of mind-expanding drugs (r = .23, p < .001). Similar 
to the 18% of Blackmore’s (1982) study, 22% of the 
Myers et al. sample reported the occurrence of OBEs, 
with 42% of these having used mind-expanding drugs 
compared to only 20% using such drugs among those 
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not reporting OBEs. Furthermore, 50% of the OBE 
experience group (n = 45) reported some psi-related 
experiences during drug taking, compared to only 4% 
of the non-OBE group (n = 155), perhaps indicating a 
commonality in the etiology of drug-induced psi and 
OBE experiences. 
Although these surveys (Blackmore 1982; 
Blackmore & Harris, 1983; Myers et al., 1983) suggest 
that the use of psychedelic substances is an important 
correlate of OBEs in the student population, this 
relationship is less pronounced in other populations. A 
later randomized postal study (Blackmore, 1984) with 
a sample of people who had reported OBEs revealed 
that only 18% of respondents reported OBEs occurring 
after taking drugs and medicines (type not specified). 
Blackmore (1992) concluded that hallucinogenic drugs 
undoubtedly help induce the OBE and were more useful 
for this than other drugs (e.g., stimulants, tranquillizers, 
sedatives, and alcohol), although she added that OBEs 
still occur rarely with psychedelic drug use and there was 
no specific OBE-inducing drug, despite Lilly’s (1978) 
assertion that ketamine is virtually a chemical road to 
the OBE. However, Blackmore (2005) later reported an 
OBE in a self-experiment with ketamine and conceded 
that, more so than other drugs, ketamine “often involves 
feelings of body separation” (Blackmore, 2003, p. 356). 
The Blackmore OBE surveys (Blackmore 
1982, 1984, 1986; Blackmore & Harris, 1983), and 
that of Myers et al. (1983), support the findings of the 
earlier survey of psychic experiences by Palmer (1979). 
In Palmer’s study, a higher percentage of the student 
sample than the townspeople sample reported OBEs (S: 
25%; T: 14%; p < .01), which Palmer attributed to the 
likely greater use of mind-expanding drugs among the 
student sample. Of the townspeople, 7% reported the 
use of mind-expanding drugs compared to 32% of the 
student population, although Palmer suspected that the 
student figure was a gross underestimate, possibly due 
to the illegality of drug use or the interpretation of the 
term “mind-expanding drugs” to exclude marijuana. It 
is not specified why Palmer should consider the student 
sample to be less likely to report their drug-use than the 
townspeople. In addition, 13% of the townspeople and 
21% of the students reporting OBEs said that at least one 
OBE had occurred under the influence of such drugs, 
figures that compare more similarly to the 18% reported 
for the general OBE population (Blackmore, 1984) 
than to the 37% and 42% in the student OBE groups 
(Blackmore, 1982; Myers et al., 1983, respectively). In 
a review of the OBE survey literature, Irwin (1994) 
agreed with Palmer that the higher reports of OBE 
experiences among students (20-48% compared to 
8-15% in the general population) were probably due in 
part to students’ more frequent experimentation with 
“psychotropic” drugs. However, Irwin suggested that it 
was probably also due in part to other factors, such as 
education and familiarity with surveys. 
Using Palmer’s (1979) questionnaire, Kohr 
(1980) failed to find any relationship between OBEs 
and drug use with the members of the Association for 
Research and Enlightenment—previous criticisms still 
standing—although Usha and Pasricha (1989a, 1989b) 
did find such a relationship with Indian students. The 
occurrence of OBEs in the Indian sample was positively 
associated with the use of mind-expanding drugs (chi-
squared = 6.87; p < .01) supporting Palmer’s findings, 
although no proportion was given for comparison. Tart 
(1993) also found that 44% of marijuana users reported 
OBEs, with 58% of these indicating that their OBE 
occurred since using marijuana, with 54% of those 
experiencing OBEs reporting at least one experience 
whilst actually under the influence of marijuana (Tart, 
1971). Most of Tart’s sample were also students (72%), 
supporting Alvarado’s (2000) suggestion that the 
relationship linking psychedelics with OBEs shown 
in student populations is not evident among the non-
student populations, although this assertion is arguably 
too exclusive of non-student drug-users. For instance, in 
surveys with psychedelic-users, DeGracia (1995) found 
that 40% had an OBE while under the influence, and 
in Kjellgren and Norlander’s (2000) sample, of which 
only 25% were students, OBEs under the influence of 
psychedelics were reported as 53%, a figure comparable 
to Tart’s marijuana group (54%). 
Reports of OBEs are also prevalent in other 
surveys among users of dextromethorphan (White, 
1997). The OBE has also appeared within numerous 
experiential reports of those who have used either 
nitrous oxide or ether (Crookall, 1961, 1964; Schroll, 
2011), LSD (Eastman, 1962; Grof, 1975, 1980; Lilly, 
1969; Whiteman, 1965), PCP (Rudgley, 2000), DMT 
(Strassman, 2001), 4-HO-MET (Kjellgren & Soussan, 
2011), Salvia divinorum (González, Riba, Bouso, 
Gómez-Jaraboa, & Barbanoj, 2006), pituri (Australian 
Institute of Parapsychological Research, 2004), 
harmaline and ayahuasca (Andritzky, 1989; Bianchi, 
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1994; Luna & White, 2000; Naranjo, 1967; Roney-
Dougal, 1986, 1989), a host of other plant psychedelics 
(Schultes & Hofmann, 1992), and even certain simple 
carbon dioxide and oxygen gas mixtures (Meduna, 
1950). That OBEs are also frequently reported to occur 
with the use of ketamine (Blackmore, 2003; Curran & 
Morgan, 2000; Jansen, 1997a, 1999, 2001; Lilly, 1978; 
Muetzelfeldt et al., 2008; Pomarol-Clotet et al., 2006), 
even apparently veridical ones (Hanna, 2003), is further 
echoed by a widely distributed UK Department of 
Health (2004) information booklet, aimed at teenagers, 
subtitled Facts about Drugs, that states the primary 
experiential effect of ketamine is an OBE. Furthermore, 
a taxonomic survey of psychoactive substance use 
phenomenology found that, out of a possible 17 different 
transpersonal experiences, OBEs (to another dimension) 
were the primary experience of both DMT use and 
ketamine (Luke & Kittenis, 2005). Indeed, a recent 
online survey (Wilkins, Girard, & Cheyne, 2011) of 
192 recreational drug users found that ketamine was 
the primary predictor of OBEs among a number of so-
called recreational drugs (alcohol, cannabis, MDMA, 
amphetamine, and LSD/hallucinogens), though DMT 
was not listed specifically. It is also documented that 
the ancient Indian psychoactive sacramental, Soma, was 
capable of inducing OBEs (Spess, 2000). 
Early OBE researchers were well aware of 
the occurrence of these experiences with psychoactive 
drugs and categorized them differently from OBEs 
with “natural” causes, suggesting that they were of a 
different type (Eastman, 1962) and of inferior quality 
(Crookall, 1961, 1972). Blackmore (1986) disagreed, 
suggesting that a distinction between drug and non-
drug experiences was not evident. Similarly, Grosso 
(1976) stated that both drug and non-drug OBEs have 
the same characteristics and that the OBE is the extreme 
manifestation of a normal human process. Grosso 
further proposed that drug states nicely demonstrated 
this continuum of out-of-bodyness by exhibiting a 
range of body-image alterations, from feeling taller to 
being completely bodiless, offering the most promising 
means of experimental OBE induction (see section 1.4 
for a discussion). Nevertheless at this time, a systemic 
comparison of the various chemically-induced OBEs and 
more spontaneous ones is long overdue.
A recent survey substantiates Grosso’s (1976) 
notion by finding that 32% of a sample of 28 first-
time users of ayahuasca report alterations in self-body 
image, ranging from fusion with the environment to 
the complete separation of the conscious self from the 
body. All respondents were new members to one of two 
particular Brazilian syncretic Christian churches that 
use the jungle decoction ayahuasca as a sacramental 
(Barbosa, Giglio, & Dalgalarrondo, 2005). 
3.4 Summary of Survey Research 
 In summary, the findings from the survey 
research indicate a small but consistent relationship (r = 
.16 to .25) between belief in the anomalous/paranormal 
and drug use, although the size of this relationship 
was more pronounced for the marijuana users in 
Tart’s (1993) study. Furthermore, these studies support 
the hypothesis that psychedelics can induce some 
paranormal phenomena, although the same arguments 
for and against the genuineness of field reports (section 
2.4) also prevail here. In the surveys reported here, with 
either student or general samples, those reporting ESP, 
apparitions, and anomalous/paranormal experiences were 
found to be significantly more likely to use psychedelics. 
One study found the same for recurrent spontaneous 
PK (sometimes called poltergeist phenomena) as well, 
although only tentatively (Palmer, 1979). Furthermore, 
of those reporting the use of psychedelics, 18-83% 
reported psi experiences—most commonly telepathy 
but also precognition—actually occurring during drug 
use, with heavier users reporting more experiences where 
specified. Yet, the occurrence of PK during drug use 
was only reported among a very small proportion of 
marijuana, psilocybin, mescaline, and LSD users. OBEs 
are also an occasional or common feature of psychedelic 
experiences and are reported to occur with a wide variety 
of drugs and wide variety of users, particularly students. 
A weak relationship between paranormal 
experiences, the use of psychedelics, and kundalini 
experiences has also been found in two studies, and 
there is also a weak, but repeated, correlation between 
transliminality, drug use, and paranormal experience 
with Australian psychology students. Where specified, 
the relationship with paranormal experiences, belief 
in the paranormal, transliminality, and tolerance of 
ambiguity is reduced compared to psychedelics with 
respect to cocaine, heroin, and alcohol, perhaps reflecting 
Metzner’s (2005) classification of these as consciousness-
contracting drugs. The same is also true for the negative 
relationship with the fear of psi found with psychedelics, 
which is not apparent with heroin and actually reversed 
with alcohol, although replication and analyses for 
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specific classes of drugs is necessary. Correlations between 
self-reports of cannabis use and thought transmission 
in psychiatric research are apparent, often indirectly, 
though such experiences are also more widely commonly 
reported in the apparent absence of pathology, with or 
without cannabis. Many of the surveys fail to adequately 
identify which substances lead to which experiences, 
although a switch to such taxonomic research is now 
evident (Luke & Kittenis, 2005). 
4. Experimental ESP Research
 Several experiments have attempted to elicit 
psi directly through the controlled consumption of 
psychedelics. These experiments have been reported 
quite differently, sometimes as entire monographs in 
excess of 100 pages or at other times as footnotes within 
another published report, often without useful details 
and statistics. The majority of these experiments were 
essentially pilot studies and were mostly conducted 
during the psychedelic research period of the 1960s. 
4.1 Forced-Choice Designs
 Forced-choice designs are those in which the 
target is chosen from among just a few known target 
types, as with the classic Zener cards. Whittesley 
(1960) reported on the use of LSD (no dose specified) 
in a forced choice ESP task with 27 participants, using 
mostly psychiatric outpatients receiving psychotherapy 
(with LSD presumably). Using ESP cards concealed 
within opaque envelopes, participants performed two 
runs of 25 guesses, one before and one after dosing. 
Neither performance yielded significant deviations 
from mean chance expectation (MCE), although a 
chi-squared analysis of the extent of variance revealed 
a significant reduction in variance (p < .001) for scores 
in the experimental condition. Under the influence of 
LSD, participants had reported that the card guessing-
task was “ridiculous, petty, mundane, etc.” (p. 221), 
and Whittesley suggested such an exceptional lack of 
deviation from MCE was due to participants feeling so 
constrained. Little can be said of the methodological 
merits of this simple experiment because little detail is 
given, but it is questioned whether the variance analysis 
was pre-planned.
Making similar use of ESP symbols, Pahnke 
(1971) reported a pilot study with five participants given 
a high dose of LSD (200-400 micrograms) and tested 
8-9 hours later. The results did not reveal an increase 
from pre-drug scores for the experimental condition. 
Pahnke cited the long delay in testing from dosage and, 
somewhat similarly to Whittesley (1960), the use of an 
ESP machine with sterile symbols as counterproductive 
factors. Pahnke proposed that future research would 
benefit from the use of familiar sender-receiver pairs, 
with both under the influence, and the use of a stimulant 
(e.g., caffeine or amphetamine) along with a psychedelic 
such as 3,4-methylenedioxyamphetamine (MDA) or 
2,5-dimethoxy-4-methylamphetamine (abbreviated 
as DOM, but also known as STP). Despite Pahnke’s 
reported failure, the psychiatrist Grof (1970) reported 
his own experience taking LSD in one of Pahnke’s 
experiments in which Grof successfully described a 
remote target in each of three attempts. Grof (1970) 
aptly described the dissonance between the task and the 
experience that occurs to the psychedelic participant, 
a mixture of both complete acceptance and fear of psi, 
when he wrote: 
When I got the third correct answer in a row, the 
feelings [of a universe where no laws of time and 
space exist] were so powerful that I could not 
continue. The reason for discontinuation of the ESP 
experiment was a strange mixture of a conviction 
that it was absurd to test the obvious and, on the 
other hand, a metaphysical fear of confusion that 
would follow if I had to give up the usual concept of 
time and space and with it all the related reference 
points we feel so secure with. (p. 3)
Prior to using free-response procedures with LSD, 
Masters and Houston (1966) also experimented with 
an ESP-card guessing procedure. With each participant 
performing ten 25-card runs, only 4 out of the sample 
of 27 participants did better than chance. Those few 
participants performing better were known very well by 
the trip guide and had reported a high degree of empathy 
(with the guide presumably). Masters and Houston 
noted that participants very quickly became bored with 
the task and complained that it was “psychedelically 
immoral” (p. 90) to have them perform card guessing 
while tripping. 
As part of a larger series of individual ESP 
tests with 36 participants under the influence of 
psilocybin, Asperen de Boer, Barkema, and Kappers 
(1966) found that, in ten 25-card runs, no individual 
scored significantly better than in their own no-drug 
control condition. The results of the 29,000 ESP-card 
trials for the 36 psilocybin and 44 control participants 
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(a few participants did multiple conditions) were 
significantly above chance (p < .01) overall. However, 
a closer inspection of the results showed that, when 
compared as a group, those in the psilocybin condition 
scored higher (MCE = .2; mean correct = .214, p < .05) 
than the control condition (mean correct = .206, p = 
.09), although the difference between the groups was 
not significant. However, there is some indication that 
order effects reduced any difference between the groups, 
because the psilocybin condition always occurred after 
the control condition, possibly resulting in test fatigue, 
as described in the following section (4.2.1). 
Kugel (1977) reported very briefly on the results 
of a telepathy experiment with LSD, in which test 
scores actually declined under the influence of LSD in 
comparison to the periods before and after intoxication. 
Participants had been given trial by trial feedback and 
it was noticed that there was a very strong tendency for 
participants to respond to this feedback by responding 
with the same call after a hit and a different one after 
a miss, the latter action being known as the gambler’s 
fallacy. Analysis revealed that this feedback susceptibility 
increased under the influence of LSD, possibly accounting 
for the poorer test performance. No further details about 
the methodology or statistical results were provided in 
this paper.
In an indirect experiment with participants 
selected for good psi scoring, Palmer, Tart, and Redington 
(1976) found a positive correlation between scores on an 
automated ESP-symbol guessing task in the laboratory 
and the reported frequency of marijuana use outside 
of the laboratory, with a negative correlation between 
ESP scores and alcohol consumption (see Tart, 1993). 
However, a follow-up study (Tart, Palmer, & Redington, 
1979) failed to replicate these results, although Tart 
(1993) suggested that this was due to the difference in 
sample groups and the rising popularity of marijuana as a 
social drug rather than as a tool of self-development. Tart 
explained this with the observation that the subjective 
effects of marijuana are highly susceptible to changes in 
psychological set and expectation, echoing Weil’s (1972) 
suggestion that marijuana is primarily just an active 
placebo. Nevertheless, direct experimental telepathy 
research with marijuana by the parapsychologist Dr. 
Thelma Moss was apparently unsuccessful (Rogo, 1976), 
though no original research papers on this are readily 
available. Even so, some similar findings to the original 
Palmer et al. (1976) study were found when scores on 
a secure non-intentional forced-choice precognition 
design task with 100 participants (Luke, Delanoy, & 
Sherwood, 2008) was correlated positively (rs = .27, p = 
.008, two-tailed) with the reported number of consumed 
psychedelics over the lifetime.
Despite earlier cautions (e.g., Masters & 
Houston, 1966; Pahnke, 1971; Whittesley, 1960) 
that ESP-card tests are too boring to those affected by 
psychedelic drugs, two later studies (Tinoco, 1994; Don, 
McDonough, Warren, & Moura, 1996) found further 
support for the forced choice task boredom factor 
with the use of ayahuasca in Brazil. In a series of 825 
ESP-card guessing trials conducted in two 90-minute 
sessions with one sender and one receiver, both under 
the influence of ayahuasca, no significant deviation from 
MCE was found (Tinoco, 1994). A second automated 
ESP-card precognition test involved one of the previous 
participants in 625 trials over two separate sessions 
lasting one hour and 40 minutes each, the scores of 
which were slightly below chance but not significantly 
so. However, it is apparent that no control condition 
was evident for comparison. As in earlier studies, both 
participants reported that the tasks were boring and that 
the tests lost their meaning and importance because it 
was more important to live the visions of the moment. 
As part of a larger investigation into EEG 
variations with ayahuasca use, Don et al. (1996) 
similarly found no significant deviation from MCE with 
a small group of (presumably experienced) participants 
using the an automated ESP task under the influence 
of ayahuasca, though again, like Tinoco’s (1994) 
study, without non-drug controls. Despite the poor 
preliminary psi-task results, which Don et al. attributed 
to methodological factors, the use of ayahuasca was 
shown to significantly increase 40-Hz (gamma) activity 
within the occipital-temporal-parietal area, particularly 
when the participant’s eyes were closed. It was noted 
that amplification of this kind has often been observed 
during successful psi-tests in previous studies with gifted 
participants. Don et al. hypothesized that the reported 
psychic effects of ayahuasca were due to this particular 
40-Hz activity amplifying unconscious psi information 
to conscious levels; however, an independent ayahuasca-
EEG study by Stuckey, Lawson, and Luna (2005) failed 
to replicate the power increases in the gamma frequency 
range, but instead found increased gamma coherence 
across the cortex with ayahuasca when compared to 
control periods. 
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Unlike most of the other forced choice designs, 
a series of successful experiments were reported by 
Puharich (1959, 1962), one of which utilized a 10-image 
unseen picture-matching test with participants who had 
ingested the psychedelic mushroom Amanita muscaria. 
Preliminary exploratory work had led Puharich to 
report the subjective feeling of telepathy himself, and 
one of his gifted participants perfectly matched two 
sets of ten unseen pictures in three seconds. Controlled 
experimental work with 26 unselected participants in 
independent trials revealed an overall chance occurrence 
of hits in the control picture matching series (106/1140; 
MCE = 114) compared to the experimental group (141 
hits; p < .01), indicating a positive effect of the mushroom 
on ESP, later repeated in a telepathy-type design.
4.2 Free Response. 
 4.2.1 Psychometry (object reading). Several 
experiments have opted for a free-response design, 
which is arguably more conducive than forced choice in 
eliciting meaningful responses from participants under 
the influence, and psychometry has been especially 
popular. In an exploratory study, using a special 
sample of six mediums, Osis (1961a) administered 100 
or 125 micrograms of LSD to each of them prior to a 
psychometry test. Five performed at chance whereas one 
was extremely successful. Although further details were 
not provided about the successful participant, Osis noted 
that the others were too absorbed in either the aesthetic 
pleasure of the experience or the quest for philosophical 
knowledge. The mediums distinguished the visions from 
normal perception and stated that the LSD experience 
was unique and caused a sense of profound unity 
with the world unlike that occurring during psychic 
experiences. Osis advised continuing research with 
drugs where the experiments were brief (only 20 mins.), 
as longer sessions appeared impractical and were thought 
to result in negative scores because participants would 
lose interest. Limited information is provided about this 
study, although it is assumed that participants were not 
experienced with psychedelics.
Smythies (1960, 1987) reported a preliminary 
psychometry investigation—planned more like a remote 
viewing task—conducted in 1950 with one volunteer 
using mescaline. Although the participant was unable 
to discern the targets under adequate blind, remote-
viewing style conditions, informal questioning about 
the target location typical of psychometry tasks elicited 
promising responses. Similarly using mescaline, a series 
of pilot studies with three participants “failed in card-
guessing tests but showed encouraging success in tests 
with free material, particularly token objects” (Rush & 
Cahn, 1958, p. 300), though, unfortunately, further 
details were not given in this paper. Further to these 
preliminary reports, Marti-Ibanez (1965) gave a second-
hand account of success with mescaline in a series of 
unpublished telepathy experiments conducted at the 
Pasteur Institute in Paris. Likewise with mescaline, 
presumably in self-experiments, Breederveld (1976, 
2001) reported success in consistently winning above 
chance at roulette experiments in casinos using real 
money, although the mescaline was only one of several 
mostly successful methods. Nevertheless, Breederveld’s 
success echoes anecdotal reports concerning the 
pioneer psychedelic researcher, Al Hubbard, who, after 
apparently developing his psychic ability through the use 
of LSD (Stevens, 1988), became somewhat notorious for 
winning on gaming machines in casinos, his reputation 
being such that he was politely escorted out when he 
reached a certain limit of earning (Krippner, 2006a). 
The most extensive object-reading test of 
participants under the influence of psychedelics formed 
part of a battery of ESP tests conducted in a large-
scale psilocybin study (Asperen de Boer, Barkema, 
& Kappers, 1966). In a no-blind repeated-measures 
design, 44 no-drug control and 36 test participants 
(30 participants did one of each condition, whereas a 
few other participants did multiple conditions) given 
10 or 20 mg. of psilocybin, were individually tested 
for four hours for ESP performance with ESP-cards, 
object reading, traveling clairvoyance, telepathy, and 
clairvoyance tests regarding both people and objects. 
Using a complex system for evaluating the success of the 
free-response tests, the experimenters jointly estimated 
the degree of probability for each statement given by the 
participants and then determined the extent to which the 
probability of correct statements outweighed the number 
and probability of incorrect statements. All participants 
were considered to have performed better than chance 
overall in the object reading, traveling clairvoyance, and 
clairvoyance-for-persons tests, but those in the psilocybin 
condition were not considered to have performed better 
than those in the control condition. However, the free-
response results were combined for these three tests so 
that no separate comparisons between the groups on 
these tests were reported. Overall performance on the 
telepathy test revealed 3 hits out of 220 sessions, where 7 
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were expected by chance, making comparisons between 
the groups of little relevance, and similarly little success 
occurred with the clairvoyance-for-objects test. 
Asperen de Boer et al. (1966) concluded that it 
is not possible to induce ESP with psilocybin, although 
Bierman (1998) argued that their participants should 
be pitied for having to do such a range of boring and 
strenuous tests while tripping, a burden unlikely to be 
imposed in modern research. Parker (1975) also criticized 
the study for promoting a scientific methodology at the 
expense of interpersonal factors. Furthermore, Asperen 
de Boer et al. made little account for the methodological 
shortcomings of the psilocybin condition, even though 
they reported that more than half of the psilocybin 
participants, mostly drug novices, were distracted by 
their visions. The authors did note, however, that there 
may have been some order effects because the psilocybin 
condition always occurred after the control condition. Of 
the five participants who completed two control trials, 
four did worse in the second trial, possibly indicating 
fatigue effects independently of the drug. Asperen de 
Boer et al. also reported briefly on a previous series of 
more promising unpublished psychometry trials with 
LSD that were conducted prior to switching to the 
psilocybin, which they considered to be less distracting. 
Out of several LSD participants some exceptionally 
accurate accounts of object reading where given, for 
which Kappers (1983) later suggested only a paranormal 
explanation seemed possible.  
4.2.2 Other clairvoyance experiments. Perhaps 
the first psychedelic ESP experiment was conducted by 
the French researcher Rouhier who gave mescaline to 
six subjects, one of whom temporarily developed very 
detailed and accurate clairvoyant abilities and was able to 
describe the contents of a nearby room (Rouhier, 1925, 
1927). The same sentiment was reported by the man who 
coined the term psychedelic, Humphry Osmond, after 
his own mescaline experiences in 1951. Osmond (1961) 
also reported that, in 1957, he and his fellow researcher 
Duncan Blewett, both under the influence of mescaline, 
successfully transmitted telepathic information in an 
informal experiment to such a degree that an independent 
observer became acutely panicky at the uncanniness of 
the event, though, unfortunately, no formal experiment 
with a larger sample is reported. 
Using the more popular substances of the 1960s, 
Cavanna and Servadio (1964) reported extensively on a 
repeated-measures clairvoyance design with the alternate 
use of LSD and psilocybin in what was primarily an 
ideographic, psychoanalytic study. In a series of three 
control, five psilocybin, and four LSD trials, three 
participants performed in a single-blind (water placebo) 
free-response clairvoyance test. In each trial there were 
10 targets of combined, yet incongruous, elements 
(e.g., a foot with an eye), which Parker (1975) unduly 
criticized for being improbable. Only one participant 
had a positive attitude towards psi phenomena and all 
were inexperienced with psychedelics. Participants were 
given low doses of LSD (40, 50, and 75 micrograms) and 
psilocybin (10 mg), much criticized by Blewett (1965) for 
failing to consider the possible dose-dependent nature of 
psychedelic-induced ESP. Yet despite the low doses and 
extensive psychological screening one participant had an 
anxiety attack in the first LSD session, which the authors 
attributed to demand characteristics expressed through 
the anxiety and anticipation of the experimenters. 
The participants’ mentations were rated for 
correspondences by three experimenters and then 
independently by two blind judges, with reasonable 
correspondence between the judging groups, though 
Blewett (1965) argued otherwise. Compared to the 
control conditions, the blind judges’ results with both 
the LSD and psilocybin showed a clear improvement 
in ESP ability, with some accurate correspondence with 
about one in five of the targets for both drugs. Notably, 
no success at all was achieved in the three control 
conditions, though unfortunately no estimation of the 
probability of the results was given, nor were inferential 
statistical analyses possible because the design had no 
decoy targets in the judging process, as duly criticized 
by Smythies (1965). Although the results are positive, 
caution is raised concerning any inferences drawn from 
so few trials. Cavanna and Servadio (1964) suggested that 
further research should make use of: stronger emotional 
targets, greater emphasis on interpersonal relations, and 
use of free association rather than interview. 
A study of some indirect relevance investigated 
the effects of low-dose LSD (65 micrograms) on apparent 
subliminal perception with five participants (Freidman 
& Fisher, 1960). Participants were shown a bold image 
faded out below the subjective threshold of (conscious) 
discrimination with several layers of paper and presented 
after a blank control image in repeated trials. Analysis 
of free-response descriptions of the hidden image by 
independent judges revealed that participants gave 
significantly more accurate descriptions of the target 
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in the experimental condition under the influence of 
LSD compared to the control condition, and that these 
participants also performed significantly better with 
LSD in the experimental condition than they had done 
six weeks previously without LSD. The results were 
interpreted as indicating the enhancement of subliminal 
perception with LSD; however, they might also be due, 
partly or wholly, to the enhancement of ESP with LSD. 
This is because the design mimics an ESP-study design 
in protocol, and there is some evidence to suggest that 
ESP is an active factor in subliminal perception research 
(Stanford, 1990). Alternatively the results may be due 
to poor methodology, such as order effects, quasi-
experimental design, and expectation or other bias due 
to the lack of blind controls across all conditions and 
the repeated use of the same subliminal target image. 
Furthermore, according to Cheesman and Merikle 
(1986), the mere perception of information from between 
the subjective and objective threshold, as in this study, 
is not strictly subliminal perception, but unconscious 
perception. 
Based upon earlier recommendations to avoid 
boring and repetitive test procedures with participants 
under the influence of psychedelics, a series of pilot 
ganzfeld experiments with cannabis (marijuana) and 
psilocybin were conducted (Wezelman & Bierman, 
1997; Bierman, 1998). In the first series, Wezelman 
and Bierman utilized a no-sender auto-ganzfeld set-
up with 40 participants pre-selected for experience 
with marijuana. In a randomized crossover design, 
participants performed two trials each, one self-dosing 
marijuana condition and a control condition. All but 
four participants, who became nauseous and dropped 
out after the first session, completed both trials. A 
planned mixture of subject judging or external judging 
was used. The control condition had a hit rate of 15% 
(MCE = 25%) compared to 30% for the marijuana 
condition, and Bierman (1998) noted that the score for 
the marijuana condition was mainly due to the external 
judges, particularly one experimenter-judge who was also 
using marijuana. However, scores for the experimental 
group were not significantly different from MCE. 
Wezelman and Bierman (1997) also reported on 
findings from a no-sender ganzfeld pilot-study conducted 
with six psilocybin-experienced participants performing 
two trials each under the influence of psilocybin. There 
was no control condition. Utilizing a buddy system 
to deter bad trips, pairs of receivers performed the 
ganzfeld together. With only subject judging this time, 
participants in the psilocybin group scored 7 direct hits 
out of 12 trials (58%), a figure that even with only a 
few trials is significantly deviant from MCE (p < .05), 
although uncorrected for a stacking effect (see Milton & 
Wiseman, 1997, p. 93). 
4.2.3 Telepathy experiments. Bierman 
(1998) continued with the previous work, this time 
in a telepathy design using a within-subjects control 
condition with 20 psilocybin-experienced participants 
who each performed one control and one psilocybin 
ganzfeld trial with a sober sender. Participants in the 
psilocybin condition scored at chance (25%), whereas 
in the control condition they performed slightly below 
(20%), with no significant difference between the two. 
However, a post hoc analysis of the results for negative 
and positive clips revealed an interaction between target 
emotionality and drug state, with a much higher hit 
rate for positive clips (44%) than negative clips (8%) in 
the psilocybin condition and a reversal of this effect in 
the control condition. This interaction was explained in 
terms of psilocybin participants possibly detecting the 
positive ESP targets, but blocking the negative images 
to deter bad trips, given that participants were tripping 
alone this time; however, the reverse effects for the 
control condition are not as easily explicable. Bierman 
interpreted this result as suggesting that psychoactive 
drugs affect psi performance and that target emotionality 
and the psychological set of the participant may interact 
to alter the results. It is also worth noting that ganzfeld 
experiments with psychoactive drugs are likely to induce 
a unique, possibly combined, state of consciousness, 
unlike the usual drug or ganzfeld experience alone, 
given that the ganzfeld environment is considered by 
many scholars to already induce a unique kind of ASC 
(e.g., Wackerman et al., 2000). However, this idea needs 
further verification.   
Coming from the field of psychedelic 
experimentation rather than parapsychology, towards 
which they reported being skeptical, Masters and 
Houston (1966) conducted a series of ESP experiments 
in which they demonstrated a much greater degree than 
their contemporaries of familiarity with the effects of 
the drugs being used. They provided an experienced 
trip guide, with whom most participants were familiar, 
and utilized experienced trippers as participants. The 
study had 62 receivers, with their guide as the sender 
of the 10 static image targets, and only the receiver 
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under the influence of LSD. Using independent judges, 
the majority of the 62 receivers (77%) gave free-recall 
responses approximating the target at least 2/10 times, 
with five of these participants approximating the target 
image 7/10 or 8/10 times. The remaining 14 participants 
(23%), who performed worse, were either unknown 
to the guide, anxious, or primarily interested in their 
own personal psychological narrative rather than the 
ESP task, though these observations may be post hoc. 
Sometimes, receiver statements also matched non-target 
thoughts of the sender. But Parker (1975) noted that 
non-verbal communication from the guide could not be 
ruled out. Once again, no estimation of the probability 
of describing the target image is known, because no 
decoy images were used in the judging process and no 
comparison was made to a control condition to establish 
if LSD actually improved scores. Nevertheless, accuracy 
rates were similar to those reported in the clairvoyance 
procedure of the same nature by Cavanna and Servadio 
(1964), where LSD and psilocybin scores exceeded 
those in control conditions. Cavanna and Servadio 
further reported an exploratory sender-receiver telepathy 
design with one LSD trial and one control, where only 
the receiver took LSD. The results indicated accurate 
comparisons in approximately one in three of the targets 
for LSD, with a rate of only one in ten for the no-drug 
control condition.
Following up from a previous forced-choice 
ayahuasca ESP study (Tinoco, 1994), Tinoco (2011) 
conducted a free response task in 1995 with three 
participants under the influence of ayahuasca acting as 
senders and receivers in a telepathy-type task. No use 
of decoy targets was made in the judging procedure, 
nevertheless three independent judges concluded that 
there was no correlation between the target and the 
response in any of the 15 trials; however, no exact 
probability of getting a hit can be calculated with 
this method, and the interpretations of the judges are 
subjective. Furthermore, no control group was used for 
comparison, it is not clear how the targets for sending 
were initially chosen, and participants complained that 
they were not getting any visual imagery and, as with the 
two previous ayahuasca studies, that the task was boring 
in such a state. 
Finally, Puharich (1962) followed up his earlier 
success at clairvoyance with Amanita muscaria with a 
demonstration for four Los Angeles news reporters, who 
also acted as participants and who were either skeptical or 
hostile towards the idea of drug-induced psi. The design 
relied on a computer-recorded random number-series 
guessing task with a non-drugged sender elsewhere, 
though where was not specified so sensory leakage 
cannot be ruled out. Participants scored at chance in the 
control condition (35 hits in 297 trials, nonsignificant) 
and after ingestion of A. muscaria repeated the test 
(average 40 mins. later) and made a combined score of 65 
hits in 432 trials (p < .005). Scoring returned to chance 
after two and half hours, as they had in the previous 
clairvoyance experiment, although participants still 
reported feeling that their intuition was active. Puharich 
(1962) attributed the results to the neurochemical 
action of cholinergia heightening the ESP function by 
activating the parasympathetic functions (slow heart 
rate, etc.) indicative of the trance state. However, 
this explanation is somewhat erroneous because the 
psychoactive principles in A. muscaria—muscimol and 
ibotenic acid—can both calm and stimulate the central 
nervous system, respectively, whereas the cholinergic 
chemical, muscarine, is now known to be only a trace and 
psychologically inactive constituent of the mushroom 
(Michelot & Melendez-Howell, 2003). There is also the 
possibility that optional stopping occurred in this latter 
experiment as indicated by the different number of trials 
in the control and experimental conditions, and Krippner 
(2006a) also raised concern that Puharich’s research, as 
with Masters and Houston (1966), was reported in a self-
authored book rather than a peer-reviewed journal. 
4.3 Summary of Experimental Research
 Due to the exploratory nature of most of these 
experiments, it is difficult to fully assess their efficacy 
using psychedelics to produce ESP (no PK experiments 
having been attempted). In most cases this could have 
largely been improved with an adequate control condition 
without order effects (Palmer, 1978), and the blind use 
of decoy targets in the judging process. Procedures using 
subjective probability estimates by experimenters (such as 
Asperen de Boer et al., 1966) are now virtually obsolete 
in parapsychology because they are so difficult to assess 
and are prone to bias (Parker, 1975). In the one ESP-
card experiment to use a control condition, scores in the 
psilocybin condition were significantly different from 
chance and were also superior to the control condition, 
although not significantly (Asperen de Boer et al., 1966). 
Nevertheless, it is apparent that those experiments using 
ESP-card type symbol guessing procedures were largely 
unsuccessful compared to chance expectation. 
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 The use of the symbol-guessing procedure has 
been widely criticized for being far too mundane under 
the influence of psychedelics (Grof, 1980; Masters & 
Houston, 1966; Pahnke, 1971; Parker, 1975; Rogo, 
1976; Stafford & Golightly, 1967; Smythies, 1960; 
Tart, 1968; Whittlesey, 1960). Even so, using Amanita 
muscaria, Puharich (1962) demonstrated that forced-
choice procedures could be successful with picture-
sorting tasks. More engaging, free-response procedures 
have demonstrated at least some success in all but one of 
the studies that have used psychometry, although rarely 
with any control condition for comparison. A clearer 
indication of possible psychedelic-induced ESP, even 
at times in comparison to a control condition, comes 
overall from the clairvoyance and telepathy designs, 
except for the Asperen de Boer et al. (1964), Tinoco 
(2011), and the marijuana ganzfeld studies (Wezelman 
& Bierman, 1997). Replication, however, is needed 
and, in some cases, with better methodology and pre-
planned analyses. It remains curious that no formal 
explicit experiments with precognition or PK have been 
performed, particularly the former because powers of 
divination are traditionally attributed to many plant 
psychedelics. 
5. Methodological Critique 
of Experimental Research
 When consideration is given to what has been 
learned from these largely pilot studies, experimenters 
and commentators alike have highlighted the difficulties 
involved in attempting to test for psi with participants 
who have taken a psychedelic. Aspirin de Boer et al. (1964) 
suggested that the participant’s willingness to perform 
in the task was important, but given that participants 
have difficulty maintaining alertness, self-control, focus, 
interest, and orientation to the task (Edge, Morris, 
Palmer, & Rush, 1986; Millay, 2001; Rogo, 1976), it 
seems much more important to consider the participant’s 
“capability” to perform in the experiment rather than 
their mere willingness. Parker (1975) notes that a 
participant’s increased sensitivity to subtle influences 
under psychedelics is both a boon and a bane to research. 
Indeed, using psychedelics to induce psi is a double-edged 
sword, namely all of the reasons cited in the introduction 
that make such research alluring also make participants 
poor test subjects. This is because participants may 
become engrossed in the experience (Rogo, 1982), the 
aesthetic rapture (Osis, 1961a; Smythies, 1960), the quest 
for philosophical knowledge (Osis, 1961a), a deep soul-
searching self-examination (Blewett, 1963), one’s own 
personal drama (Millay, 2001; Parker, 1975), and the 
flow of thoughts (Ryzl, 1968). In addition, participants 
may have difficulty communicating because of the lack 
of adequate language (Lilly, 1969), the overwhelming 
flood of ideas and emotions (Ryzl, 1968) and the speed of 
change of the internal experience (Blewett, 1961b, 1963). 
The experience of dissociation (e.g., with ketamine) can 
also hinder communication when participants become 
no longer present or aware of their physical environment 
and, as Huxley (1961b) pointed out, there is a need to 
assure participants of their identity once constructs 
of space and time disappear. Blewett (1961a) further 
warned of other unwanted psychological reactions that 
may occur if participants attempt to either escape from 
or rationalize their experience. 
However, it is apparent that these obstacles to 
research may be greatly alleviated or even eliminated if 
participants are experienced with the use of psychedelics 
(Blewett, 1963; Parker, 1975; Tart, 1977). Indeed, about 
a quarter of inexperienced participants are expected to 
have intense spontaneous mystical experiences during 
their first trip (Wulff, 1997, 2000). Yet, very few of the 
studies reviewed here (only Bierman, 1998; Masters & 
Houston, 1966; Wezelman & Bierman, 1997) specifically 
reported the use of participants experienced with these 
psychedelics, although it is worth noting that those that 
did were relatively more successful than those that used 
inexperienced participants. Further to this, it has been 
suggested that experienced psychedelic participants 
can be better trained to stabilize their experience 
(Millay, 2001; Tart, 1977) and may even naturally train 
themselves to stabilize experiences through repeated 
use (Levine, 1968). Regardless of training, it has been 
strongly advised that participants be allowed to stabilize 
their experience before testing begins (Blewett, 1963, 
1965; Millay, 2001; Parker, 1975; Tart, 1977). Pahnke 
(1968) further recommended an 8- to 12-hour pre-dose 
preparation period when working with terminal cancer 
patients, although Ludwig (in Tart, 1968) questioned 
the necessity of this in a parapsychological context.  
Stabilization of the experience may even 
be expedited by inducing hypnosis prior to drug 
administration (Parker, 1975; Tart, 1968) in what has 
been called the “hypnodelic” state (e.g., see Levine & 
Ludwig, 1965; Ludwig 1968; Tart, 1967). Alternatively, 
Ryzl (1968) reported re-inducing LSD states through 
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hypnosis, as is also reported elsewhere, although it was 
uncertain how successful this was (Ludwig, 1968), though 
success inducing other drug states (e.g., MDMA, heroin) 
has also been reported (Hastings, 2006; Hastings et al., 
2000; Ludwig & Lyle, 1964). Similarly, Farber (2000) 
has described the successful re-induction of psychedelic 
states using hypnotic anchoring techniques available 
in neuro-linguistic programming. Perhaps, the entire 
psychedelic experience can be stabilized and anchored 
during test trips with experienced users and then 
later re-induced, with or without hypnosis, so that no 
psychedelics are actually taken during the test procedure. 
Testing for psi under such “controlled flashbacks” may 
overcome most of the stipulated problems, and have the 
added advantage of investigating Rogo’s (1976) question 
of whether it is the neurochemical action of the drugs or 
the state induced that can seemingly produce psi. 
Although some researchers (Halliday, 1961; 
Nicol & Nicol, 1961; Paterson, 1961a; Smythies 1960; 
Tart in Levine, 1968) suggest that using good psi scorers, 
psychics, and mediums in drug studies would improve 
scoring, Eileen Garrett (1961b) noted that although 
LSD enhanced her mediumistic experience it would not 
improve forced choice test-scores. Echoing this, the Osis 
(1961a) experiment has shown that using mediums did 
not prove any more successful than the use of normal 
participants in the other psychometry experiments. This 
was probably due to all the problems mentioned already 
that occur more with inexperienced psychedelic users, 
indicating that sample selection should primarily seek 
to select experienced users over psi-effective participants, 
although, presumably, ideal participants would be both, 
though not necessarily.
Considering aspects of timing, several authors 
have offered advice, though no formal studies have been 
conducted. Both Ryzl (1968) and Grof (1980) suggested 
that the optimum period for testing psi during the LSD 
session was towards the end when the effects were leveling 
off, as in the Masters and Houston (1966) experiments, 
yet Pahnke (1971) disagreed. From extensive personal 
experience, Copley (1962) suggested testing for ESP once 
the trip had finished. As regards to the duration of the 
psi-task, rather than the extended test periods favored 
by some researchers (e.g., Asperen de Boer et al., 1964; 
Tinoco, 1995), Osis (1961a) suggested 20 minutes should 
be the maximum for optimum performance.  
Some consideration has also been given to 
the optimal substance. Pahnke (1971) recommended 
combining stimulants with psychedelics, whereas 
Asperen de Boer et al. (1966) chose psilocybin over LSD, 
due to it being milder, with which Cavanna and Servadio 
(1964) agreed. Indeed, LSD has a much longer duration 
of action than psilocybin and as Blewett (1963) noted, 10-
hour trips are hard to staff. Ryzl (1968) also questioned 
the utility of LSD in psychedelic psi testing and proposed 
that the ideal substance, if it can be synthesized, should 
inhibit cortical activity to suppress the stream of 
thoughts, depress sub-cortical activity to block incoming 
stimuli and excite spheres of the cortex involved in ESP 
production, yet maintain rational insight, and increase 
suggestibility. However, such a designer drug is far in the 
future, though such psychochemical engineering may 
one day be possible (Brown, 2012b); moreover, there 
are an increasing number of ethnobotanical substances 
becoming known that have traditionally been used for 
psychic purposes, which have not yet been thoroughly 
tested, or even tested at all (e.g., Salvia divinorum). 
Tart (1993) further suggested that marijuana was 
an ideal substance for psi experimentation because of its 
wide familiarity within the public, its mild psychedelic 
qualities and its reputed ability to induce psi, experientially 
at least. Puharich’s (1962) apparent repeated success with 
Amanita muscaria also needs replicating. Furthermore, 
other non-psychedelic chemical psi research, such as de 
Pablos’ (2002) unsuccessful first-person precognitive-
dream drug-study, could also be replicated with the 
use of psychedelic substances that have actually been 
reported to induce psi in dreams. For instance, there 
are reports of precognitive dreams, by both traditional 
users and by modern consciousness researchers, with 
substances such as Calea zacatechichi (Devereaux, 1997; 
Díaz 1979; Mayagoitia, Díaz, & Contreras, 1986), Silene 
capensis (Hirst, 2000, 2005; Sobiecki, 2008, 2012), 
and tree datura (Brugmansia; Metzner, 1992; Schultes 
& Hofmann, 1992). Other substances seem best 
suited to other experimental designs too, for example, 
telepathy-like experiments might also benefit from the 
empathogenic effect of substances like MDMA, as the 
one participant under its influence in a remote detection 
experiment did exceedingly well (Brown, 2012a). The use 
of a placebo in a double-blind or blind control condition, 
as in Cavanna and Servadio (1964), is of questionable 
utility in this type of experiment because at anything 
less than sub-threshold doses the participant is likely 
to easily detect the effects of the drug; nevertheless, 
researchers should be aware that placebo drug effects 
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have been demonstrated in ESP research when coupled 
with positive false feedback on task performance (Pitman 
& Owens, 2004).
Several researchers have also commented on 
the importance of dosage (e.g., Braud, 2002; Levine, 
1968). Blewett (1961b) warned that giving participants 
low doses of LSD may not be sufficient to break through 
the barrier between the normal and the full-blown 
psychedelic state and can be merely disorientating rather 
than transformative, and he later suggested that doses 
up to 1,500 micrograms of LSD (a very large dose) need 
investigating, because ESP might be dose dependent 
(Blewett, 1965). Support for this logic is also evident 
in escalating dose research with DMT (Strassman, 
2001). It is additionally advised that experienced 
participants control their own dosage (Tart, 1977), as 
in the experiment by Wezelman and Bierman (1997). 
Participant’s self-reports of the depth of the altered state 
were also considered better than dosages as indicators 
of subjective effects (Tart, 1977). Self reports using 
the Hallucinogenic Rating Scale were also considered 
better indicators of dosage than physiological measures 
(Strassman, Qualls, Uhlenhuth, & Kellner, 1994), 
though the use of a scale of transpersonal experience, 
such as the Self-Expansiveness Level Form (Friedman, 
1983; Pappas & Friedman, 2007), would also likely 
be fruitful in discerning the relevant depth of the 
psychedelic ASC. Furthermore, some researchers (e.g., 
Parker, 1975; Tart 1968, 1977) have noted that the 
issue of dosage is largely irrelevant in comparison to the 
influence of the psychological factors of set and setting, 
as originally noted in psychedelic research by Leary, 
Litwin, and Metzner (1963). In discussion of this, Vayne 
(2001) suggested that the influence of psychological 
factors on psychoactive drugs can vary their effects so 
much that the drug can be thought of primarily as an 
experience, composed of set, setting, and substance. 
Factors considered important in determining 
psychological set include the participants’ expectations, 
attitudes towards themselves, idiosyncratic perceptions, 
and emotional orientation to the experiment (Levine, 
1968; Tart, 1968). It is also deemed imperative to 
engender a sense of self-surrender, acceptance, and 
trust (Blewett, 1963). Factors considered important in 
determining psychological setting include those that 
are ordinarily considered under demand characteristics 
(Parker, 1975; Tart, 1968, 1977), particularly the 
experimenter’s attitude, which should be warm, friendly, 
and supportive (Blewett, 1963). Psychological issues 
induced through interpersonal relations within the 
laboratory become magnified when participants are on 
psychedelics (Blewett, 1963; Parker, 1975). Cavanna 
and Servadio (1964) highlighted this when one of 
their participants had an anxiety attack concurrent 
with their own anxiety, which led them to advise that 
the experimenters themselves should be experienced 
users of the psychedelic substance under investigation, 
as also advised by Strassman (2001). Tart (1968) also 
recommended that the experimenter should guide 
the experience towards the goal of the study, and has 
criticized previous work for assuming psychedelic states 
automatically induce psi, because, as noted by Tart, 
Osmond, and Beloff (in Levine, 1968), and Puharich 
(1959), in traditional scenarios the shamans who use 
these substances usually have extensive training and 
experience. It is further suggested that the experimental 
task be shaped to the state of the participant, not vice 
versa (Tart, 1977), and utilize the strong motivation, 
directed awareness, and complex ritual that is found in 
shamanism (Copley, 1962; Grof, 1980; Tart, 1968). Grob 
and Harman (1995) have also urged the integration of 
aspects from shamanic practices into scientific procedure 
so that there is attentiveness to factors of set and setting, 
such as intention, expectation, preparation, group 
identification, and formalized structure, as well as the 
integration of the experience in the following months. 
Indeed a multi-method approach to studying psychedelic 
shamanic practices is advised, so that ethnography can 
inform suitable experimentation (Giesler, 1984, 1985; 
Luke, 2010a). Nevertheless, Storm and Rock (2011) 
pointed out that, in psi research with psychedelics, 
researchers need to be aware of the difference between 
shamanic techniques and merely shamanic-like 
techniques; for example, the latter may lack the purpose 
of serving one’s community. Furthermore, Tart (1977) 
has recommended the implementation of mutual 
research, where participants are considered as co-
investigators, to reduce experimenter bias and enhance a 
sense of participation, trust, and motivation.
6. General Summary and Conclusions
Even though the subjective paranormal experiences, clinical observations and anthropological reports are 
subject to all the usual criticisms and rebuttals that apply 
to non-experimental cases (e.g., see Stokes, 1997) there is 
a growing body of reports, rooted in thousands of years of 
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traditional psychedelic use, that supports the notion that 
genuine paranormal phenomena do occur. Nevertheless, 
as evidence this data is not scientifically rigorous, yet it has 
great value in mapping the phenomenological terrain of 
paranormal experiences with psychedelics. This body of 
reports is further supported by correlations from surveys 
linking psychedelic use with the increased reporting of 
paranormal experiences and belief in the paranormal, 
although again, self-reports have more phenomenological 
merit than evidential value. Furthermore, even though 
it can be considered little more than exploratory at this 
stage, the experimental evidence is more positive than 
not and proves promising so far, illuminating both 
methodological pitfalls and possibilities. 
It is apparent that parapsychopharmacology 
is a multidisciplinary endeavor pooling expertise 
from anthropology, ethnobotany, phytochemistry, 
neurobiology, psychopharmacology, psychiatry, 
psychotherapy, transpersonal psychology, and indeed 
parapsychology. It also owes much to the non-academic 
explorers of consciousness, be they shamans, occultists, 
or psychonauts. It is a branch of research that is still very 
much in its infancy, and, along with other fields conducting 
research with the use of psychedelics, has been operating 
very quietly since the late sixties until a gentle turn in the tide 
during the last decade or so has seen experimental research 
resumed (see Grob & Harman, 1995). Nevertheless, 
further experimental research continues to need strict 
ethical and often governmental approval before it can 
proceed, requiring lengthy applications (see McKenna, 
2004; Strassman, 2001). Several years ago, Tart (1977) 
recommended bypassing these difficulties by casually 
enrolling participants who were already using psychedelics, 
rather than having the experimenter administering the 
substances directly. An example of this kind of experiment 
involved several thousand Grateful Dead fans, renowned 
for their psychedelic consumption, who acted as senders in 
a series of dream telepathy experiments with some success 
(Krippner, 1999; Krippner, Honorton, & Ullman, 1973; 
Roberts, 2004). Indeed, taking what Giesler (1984, 1985) 
calls a psi-in-process approach and keeping naturalistic 
variables intact, group experiments may be one way to 
access the kind of group telepathy experiences that people 
tripping in groups sometimes report (e.g., Grey, 2007; 
Nuttal, 1970; Stevens, 1989; Wolfe, 1971), especially 
on DXM (Luke & Kittenis, 2005). However, without 
the grounded and controlled atmosphere of a concert or 
shamanic ceremony, psychedelic group ESP experiments 
run the risk of turning into bacchanalian scenes, as once 
witnessed by Puharich’s wife (Hermans, 1998). 
However, now resumed, direct parapsychological 
research with psychedelics needs expanding beyond 
the Netherlands and Brazil—the only place where 
experimental psi-chedelic research has been conducted 
since the 1970s—and treating these substances like any 
other drug worthy of investigation within a medical or 
therapeutic context has recently proven a fruitful means 
of inquiry for many researchers (Doblin, 2004; Grob & 
Harman, 1995), although psi research does not readily 
attract such funding at the present time. Nevertheless, 
it should be noted that psychedelics are considered as 
sacramentals by the spiritual and religious groups that 
use them and they must be utilized and researched with 
respect. It is also clear that besides trying to replicate the 
promising free-response studies, further experimental 
psychedelic research should utilize protocols that 
maximize psi effects, and this work can then 
simultaneously enhance process research methodology 
by indicating optimal conditions for psi through the 
psychologically magnifying effects of these substances. 
For instance, Bierman’s (1998) psychedelic psi research 
may have revealed the apparent psychic blocking of 
negative images, and, from earlier experiments, forced-
choice tasks are clearly too mundane. Research should 
also seek to study these substances in the shamanic 
context in which they have most effectively been used, 
designing appropriate test protocols for traditional 
settings. A recent example of which is Hirukawa et al.’s 
(2006) apparently successful demonstration of psi using 
a field random event generator in an ayahuasca ritual 
with the Santo Daime church in Brazil.  
Additionally, following in the footsteps of 
William James, there has already been some return 
to self-experimentation with psychoactive drugs by 
de Pablos (2002, 2004), who has developed a viable 
protocol for testing one’s own precognitive dreaming 
abilities with drugs, which might easily be adapted 
to waking experimentation as well. All experimental 
research should also be designed and conducted with 
an appreciative consideration of Tart’s proposals for 
the creation of state-specific sciences (Tart, 1972, 1998, 
2000, 2001). In the future, parapsychologists might ask 
their participants about their drug use, and researchers 
investigating the use of psychedelics might once more 
include questions relating to paranormal experiences 
(e.g., Echenhofer, 2005). Furthermore, with an ever 
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growing number of substances being discovered and a 
large natural data pool of psychedelic users, there is a 
need for more thorough and focused phenomenological 
research that investigates and identifies the types of 
paranormal experience that occur through the use of 
each of these diverse psychedelic substances (Luke, 
2004a, 2004b, 2004c; Luke & Kittenis, 2005). 
Finally, there is much that can be offered 
to transpersonal studies from the investigation of 
parapsychopharmacology, and vice versa. Certainly it is 
clear that no study of the extraordinary phenomena of the 
psychedelic state would be complete without the insights 
and perspective of transpersonal psychology. Indeed, 
many of the exceptional experiences encountered with 
psychedelics involve parapsychological elements and yet 
they also go beyond the ordinary scope of parapsychology 
into the wider transpersonal realms (Luke, 2012b), such 
as entity encounters (e.g., Luke, 2011b) and profound 
mystical experiences (Luke & Kittenis, 2005). It is also 
somewhat inevitable then that this course of research is 
as likely to culminate in transformation for the researcher 
as it is in evidence for the genuine existence or otherwise 
of psychedelically induced paranormal phenomena (Luke, 
2011c). It is also illuminating at this point to consider this 
research in terms of Tart’s (2002) evaluation of these related 
fields of enquiry, where parapsychology is to transpersonal 
psychology what physics is to engineering: One researches 
the fundamental technical nature of the subject matter so 
that the other may apply it. In the current  case a great deal 
can be learned, as Tart reminds, about the fundamental 
nature of mind through the study of parapsychology 
and—by looking to the psychedelic dimension—about 
the neurochemical mediation of exceptional aspects of 
consciousness in particular. Ultimately, however, it is 
down to transpersonal psychologists how they use this 
knowledge and apply it, though, fortunately, the history 
here tells us that wisdom usually prevails. 
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